Infusion pump systems and methods

Description

TECHNICAL FIELD

This disclosure relates to portable infusion pump systems to deliver fluids, such as insulin infusion pump systems or the like.

BACKGROUND

Pump devices are commonly used to deliver one or more fluids to a targeted individual. For example, a medical infusion pump device may be used to deliver a medicine to a patient as part of a medical treatment. The medicine that is delivered by the infusion pump device can depend on the condition of the patient and the desired treatment plan. For example, infusion pump devices have been used to deliver insulin to the vasculature of diabetes patients so as to regulate blood-glucose levels. In some circumstances, the dosage of medicine delivered by the infusion pump acts within the patient's body over a long period of time. Such conditions, for example, may cause a patient to have an amount of non-activated insulin in his or her system even though the infusion pump is programmed to deliver the next dosage in a series of insulin dosages.

SUMMARY

Some embodiments an infusion pump system can be used to determine a user's total insulin load (TIL) that provides an accurate indication of the insulin already delivered to the user's body which has not yet acted. In particular embodiments, the TIL can account for both the bolus deliveries and the basal deliveries that have occurred over a period of time. Such information can be valuable to a user when the infusion pump is operated in conjunction with a glucose monitoring device worn by the user. Moreover, the TIL information can be readily displayed to the user as a quick reference of his or her status. For example, the infusion pump system can include a user interface that contemporaneously displays the user's blood glucose value and the total insulin load, thereby enabling the user to make informed decisions regarding the current and future status of his or her blood glucose level.

In particular embodiments, a medical infusion pump system may include a portable pump housing that receives insulin for dispensation to a user. The pump housing may at least partially contain a pump drive system to dispense the insulin through a flow path to the user. The pump system also may include a controller that activates the pump drive system to dispense the insulin from the portable pump housing. The pump system may further include a monitoring device that communicates glucose information to the controller. The glucose information may be indicative of a blood glucose level of the user. The pump system also may include a user interface coupled to the controller including a display device that contemporaneously displays a glucose value indicative of the blood glucose level of the user and a total insulin load indicative of bolus and basal insulin dosages that have dispensed but not yet acted in the user.

Some embodiments of a method of operating an insulin infusion pump system may include determining a total insulin load for a particular time that accounts for a bolus insulin load, a basal insulin load, and a previous food component. The bolus insulin load may be indicative of one or more bolus insulin dosages that have been dispensed into a user from a portable infusion pump system but not yet acted in the user. The basal insulin load may be indicative of one or more basal insulin dosages that have been dispensed into the user from the portable infusion pump system but not yet acted in the user. The previous food component may be based upon previous food intake that has not yet metabolized in the user. The method also may include storing a calculated value for the total insulin load and a time value for the particular time in a computer-readable memory device of the portable infusion pump system. The method may further include displaying the calculated value for the total insulin load on a display device of the portable infusion pump system.

In certain embodiments, a method of operating an insulin infusion pump system may include receiving user input indicative of a request to suggest a bolus dosage. The method may also include receiving user input indicative of a proposed food intake to be consumed by a user of a portable infusion pump system. The method may further include receiving glucose information indicative of a glucose level of the user. Also, the method may include determining a bolus suggestion value according to a function that includes a total insulin load of the user. The total insulin load may account for (i) a bolus insulin load indicative of one or more bolus insulin dosages that have been dispensed into the user but not yet acted in the user, (ii) a basal insulin load indicative of one or more basal insulin dosages that have been dispensed into the user from the portable infusion pump system but not yet acted in the user; and (iii) a previous food component based upon previous food intake that has not yet metabolized in the user. The method may also include displaying the bolus suggestion value on a display device of the portable infusion pump system.

These and other embodiments described herein may provide one or more of the following advantages. First, the infusion pump system can be used to provide a TIL value that accurately estimates the amount of previously delivered insulin that has not yet acted in the user's body. For example, the TIL can be determined in a manner that accounts for both the bolus deliveries and the basal deliveries (not merely previous bolus deliveries). As such, the TIL values may accurately reflect basal rate changes and the impact of stopping insulin delivery or changing basal delivery for a short period of time (e.g., a temporary basal rate change). Also, in particular embodiments, the TIL can account for the user's previously consumed food in addition to the bolus deliveries and the basal deliveries. In these circumstances, the TIL values may accurately reflect both the previously dispensed insulin that has not yet acted and the previously consumed food that has not yet been metabolized. Second, the TIL information provided by the infusion pump system can provide the user with opportunities for informed decision-making when the infusion pump is operated in conjunction with a continuous glucose monitoring device. For example, the infusion pump system can include a user interface that contemporaneously displays the user's blood glucose value and the total insulin load, thereby enabling the user to make informed decisions regarding the current and future status of his or her blood glucose level. Third, the infusion pump system can include a bolus suggestion feature that accounts for the user's TIL when suggesting a new bolus of insulin prior to a meal of other food intake. For example, in response to a user's request, the infusion pump system may communicate a suggested bolus dosage of insulin that is calculated to account for the meal of other food to be consumed (e.g., a food bolus), the current difference between the user's actual blood glucose level and the targeted blood glucose level (e.g., a correction bolus), and the amount of previous basal and bolus insulin that has not yet acted in the user's body (e.g., a TIL factor).

The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 is a perspective view of an infusion pump system in accordance with some embodiments.

FIG. 2 is a perspective exploded view of an infusion pump assembly of the system of FIG. 1.

FIG. 3 is a perspective view of the infusion pump system of FIG. 1 in which the pump assembly is worn on clothing of a user, in accordance with particular embodiments.

FIG. 4 is a perspective view of an infusion pump system of FIG. 1 in which the pump assembly is worn on skin of a user, in accordance with other embodiments.

FIGS. 5 and 6 are perspective views of a pump device being detached from a controller device of the system of FIG. 1, in accordance with some embodiments.

FIGS. 7 and 8 are perspective views of the pump device of FIGS. 5 and 6 being discarded and the controller device of FIGS. 5 and 6 being reused with a new pump device.

FIG. 9 is an exploded perspective view of a controller device for an infusion pump system, in accordance with some embodiments.

FIG. 10 is a perspective view of a portion of a pump device for an infusion pump system, in accordance with particular embodiments.

FIG. 11 is a flow diagram depicting an exemplary process used to determine a user's total insulin load (TIL), in accordance with some embodiments.

FIG. 12 is a diagram depicting an example of an insulin decay curve, which may be employed in the determination of the user's TIL in accordance with some embodiments.

FIG. 13 is a diagram depicting an example of an insulin delivery pattern (constant basal delivery rate only) and a user's corresponding TIL and TIL % values, in accordance with some embodiments.

FIG. 14 is a diagram depicting an example of an insulin delivery pattern (constant basal delivery rate plus selected bolus deliveries) and a user's corresponding TIL and TIL % values, in accordance with some embodiments.

FIG. 15 is a diagram depicting an example of an insulin delivery pattern (intermittent basal delivery plus selected bolus deliveries) and corresponding TIL and TIL %, in accordance with some embodiments.

FIG. 16A is a diagram depicting an example of an insulin delivery pattern (intermittent basal delivery plus selected bolus deliveries) and a user's corresponding TIL and TIL % values, in accordance with some embodiments.

FIG. 16B is a diagram depicting an example of insulin delivery pattern (intermittent basal delivery plus selected bolus deliveries) and a user's corresponding TIL and TIL % values that account for a previously consumed food component, in accordance with some embodiments.

FIG. 17 is a flow diagram depicting an exemplary process used to determine a bolus suggestion, in accordance with some embodiments.

FIG. 18 is a perspective view of an infusion pump assembly connected to an external computer for displaying a plot of TIL data received from the infusion pump assembly, in accordance with some embodiments.

FIG. 19 is a perspective view of an infusion pump assembly displaying a plot of TIL data on a display device, in accordance with some embodiments.

Like reference symbols in the various drawings indicate like elements.

DETAILED DESCRIPTION

Referring to FIG. 1, an infusion pump system 10 can include a pump assembly 60 used to supply insulin or other medication to a user via, for example, an infusion set 70. In some embodiments, a glucose monitoring device 50 can be in communication with the infusion pump assembly 60 for the purpose of supplying data indicative of a user's blood glucose level to a controller device 200 included in the pump assembly 60. The infusion pump system 10 can be configured to supply a substantially continuous basal rate of insulin (or other medication) with user-selected bolus dosages. The basal rate can be selected to maintain a user's blood glucose level in a target range during normal activity when the user is not eating or otherwise consuming food items, and the selected bolus deliveries may provide substantially larger amounts of insulin to limit the blood glucose level during certain circumstances, such as the consumption of carbohydrates and other food items. The basal and bolus insulin dispensed into the user's system may act over a period of time to control the user's blood glucose level. As such, the user's body may include some amount of insulin that has not yet acted even while the infusion pump assembly 60 is activated to deliver additional dosages (basal, bolus, or both). In these circumstances, the infusion pump assembly 60 can be used to determine a user's total insulin load (TIL) that provides an accurate indication of the insulin which has not yet acted in the user's body. For example, as shown in FIG. 1, the controller device 200 of the infusion pump assembly 60 can include a user interface 220 configured to calculate and display the TIL value along with the user's blood glucose value, thereby enabling the user to make informed decisions regarding the current and future status of his or her blood glucose level.

The TIL information provided by the controller device 200 can be determined in a manner that accounts for both the bolus deliveries and the basal deliveries (not merely bolus deliveries alone). As described in more detail below, this process for determining the TIL value can accurately reflect basal rate changes and the effects from stopping insulin delivery or changing basal delivery for a short period of time (e.g., a temporary basal rate change). Also, in further embodiments, the TIL information provided by the controller device 200 can be determined in a manner that accounts for the user's previously consumed food (along with the previous basal and bolus deliveries). As described in more detail below, such a process for determining the TIL value can reveal the effects from both the previously dispensed insulin that has not yet acted and the previously consumed food that has not yet been metabolized. In some embodiments, data related to the TIL, such as total insulin load values and the times at which they were calculated, can be stored in a memory device (described below) of the controller device 200. This data can be used, for example, by the controller device 200 in a process to suggest a new bolus dosage based in response a user's request. For example, the bolus suggestion value can be based, at least in part, on a user's current blood glucose level, food information supplied by the user (e.g., proposed food intake), and a recently calculated TIL value for the user. Moreover, the TIL data stored in the memory device of the controller device 200 can be exported to an external computer system for analysis by a physician, the user, or both. For example, as described in more detail below, the TIL data can be presented in a plot format to assist the user and physician in making adjustments to the user's insulin delivery patterns or food intake to improve management the user's blood glucose level.

Still referring to FIG. 1, the glucose monitoring device 50 can include a housing 52, a wireless communication device 54, and a sensor shaft 56. The wireless communication device 54 can be contained within the housing 52 and the sensor shaft 56 can extend outward from the housing 52. In use, the sensor shaft 56 can penetrate the skin 20 of a user to make measurements indicative of characteristics of the user's blood (e.g., the user's blood glucose level or the like). In response to the measurements made by the sensor shaft 56, the glucose monitoring device 50 can employ the wireless communication device 54 to transmit data to the controller device 200 of the pump assembly 60.

In some embodiments, the monitoring device 50 may include a circuit that permits sensor signals (e.g., data from the sensor shaft 56) to be communicated to the communication device 54. The communication device 54 can transfer the collected data to the infusion pump assembly 60 (e.g., by wireless communication to a communication device 247 arranged in the pump assembly 60). In some embodiments, the monitoring device 50 can employ other methods of obtaining information indicative of a user's blood characteristics and transferring that information to the infusion pump assembly 60. For example, an alternative monitoring device may employ a micropore system in which a laser porator creates tiny holes in the uppermost layer of a user's skin, through which interstitial glucose is measured using a patch. Alternatively, the monitoring device can use iontophoretic methods to non-invasively extract interstitial glucose for measurement. In other examples, the monitoring device can include non-invasive detection systems that employ near IR, ultrasound or spectroscopy, and particular embodiments of glucose-sensing contact lenses. Invasive methods involving optical means of measuring glucose could also be added. In yet another example, the monitoring device can include an optical detection instrument that is inserted through the skin for measuring the user's glucose level.

Furthermore, it should be understood that in some embodiments, the monitoring device 50 can be in communication with the pump assembly 60 via a wired connection. In other embodiments of the pump system 10, test strips (e.g., blood test strips) containing a sample of the user's blood can be inserted into a strip reader portion of the pump assembly 60 to be tested for characteristics of the user's blood. Alternatively, the test strips (e.g., glucose test strips) containing a sample of the user's blood can be inserted into a glucose meter device (not shown in FIG. 1), which then analyzes the characteristics of the user's blood and communicates the information (via a wired or wireless connection) to the pump assembly 60. In still other embodiments, characteristics of the user's blood glucose information can be entered directly into the infusion pump system 10 via a user interface on the controller device 200.

Referring now to FIGS. 1 and 2, the infusion pump assembly 60 can include a pump device 100 and the controller device 200 that communicates with the pump device 100. The pump device 100 includes a pump housing structure 110 that defines a cavity 116 in which a fluid cartridge 120 can be received. The pump device 100 also includes a cap device 130 to retain the fluid cartridge 120 in the cavity 116 of the pump housing structure 110. The pump device 100 includes a drive system (described in more detail below in connection with FIG. 10) that advances a plunger 125 in the fluid cartridge 120 so as to dispense fluid therefrom. In some embodiments, the dispensed fluid exits the fluid cartridge 120, passes through a flexible tube 72 of the infusion set 70 to a cannula housing 74. The dispensed fluid can enter through the skin via a cannula 76 attached to the underside of the cannula housing 74.

In some embodiments, the controller device 200 communicates with the pump device 100 to control the operation of the pump drive system. When the controller device 200, the pump device 100 (including the cap device 130 in this embodiment), and the fluid cartridge 120 are assembled together, the user may conveniently wear the infusion pump assembly 60 on the user's skin under clothing or in the user's pocket while receiving the fluid dispensed from the pump device 100 (refer, for example, to FIGS. 3 and 4). Thus, in some embodiments, the pump assembly can operate as a portable unit that provides reliable delivery of insulin or another medication in a discrete manner.

As described in more detail below, the controller device 200 may be configured as a reusable component that provides electronics and a user interface to control the operation of the pump device 100. In such circumstances, the pump device 100 can be a disposable component that is disposed of after a single use. For example, the pump device 100 can be a “one time use” component that is thrown away after the fluid cartridge 120 therein is exhausted. Thereafter, the user can removably attach a new pump device 100 to the reusable controller device 200 for the dispensation of fluid from a new fluid cartridge 120. Accordingly, the user is permitted to reuse the controller device 200 (which may include complex or valuable electronics) while disposing of the relatively low-cost pump device 100 after each use. Such a pump assembly 60 can provide enhanced user safety as a new pump device 100 (and drive system therein) is employed with each new fluid cartridge 120.

Briefly, in use, the pump device 100 can be configured to removably attach to the controller device 200 in a manner that provides a secure fitting, an overall compact size, and a reliable electrical connection. The compact size permits the infusion pump assembly 60 to be discrete and portable. As described in more detail below, the controller device 200 of the infusion pump system can be used to provide TIL information that accurately estimates the amount of previously delivered insulin that has not yet acted in the user's body. In these embodiments, the TIL information can provide the user with opportunities for informed decision-making when the pump assembly 60 is operated in conjunction with the monitoring device 50. In addition, the controller device 200 can provide a bolus suggestion feature that accounts for the user's TIL when suggesting a new bolus of insulin prior to a meal of other food intake. Because the bolus suggestion feature accounts for the amount of previous basal and bolus insulin that has not yet acted in the user's body, the controller device 200 can provide a suitable bolus suggestion amount that generally avoids excessive stacking of insulin doses.

It should be understood that, in alternative embodiments, the pump device 100 and the controller device 200 can be configured as a single unit in which the control components and the pump drive system are arranged in a single housing. In these alternative embodiments, the pump assembly (including the controller device and the pump device) may have a different size and shape and may operate as a reusable unit that can communicate with a number of monitoring devices 50 over a period of time.

Referring again to FIGS. 1 and 2, in some embodiments, the infusion pump system 10 is a medical infusion pump system that is configured to controllably dispense a medicine from the cartridge 120. As such, the fluid cartridge 120 may contain a medicine 126 to be infused into the tissue or vasculature of a targeted individual, such as a human or animal patient. For example, the pump device 100 can be adapted to receive a medicine cartridge 120 in the form of a carpule that is preloaded with insulin or another medicine for use in the treatment of Diabetes (e.g., BYETTA®, SYMLIN®, or others). Such a cartridge 120 may be supplied, for example, by Eli Lilly and Co. of Indianapolis, IN. Other examples of medicines contained in the fluid cartridge 120 include: pain relief drugs, hormone therapy, blood pressure treatments, anti-emetics, osteoporosis treatments, or other injectable medicines. The medicine dispensed from the cartridge 120 into the user's system may act over a period of time in the user's body. As such, the user's body may include some amount of medicine that has not yet acted even while the infusion pump assembly 60 is activated to deliver additional dosages of the medicine (basal, bolus, or both). The infusion pump assembly 60 can be used to determine a user's total medicine load that provides an accurate indication of the medicine which has not yet acted in the user's body. The total medicine load can be determine by the controller device 200 in a manner that accounts for both the bolus deliveries and the basal deliveries of the medicine (similar to the process for determining the total insulin load as described below). It should be understood from the description herein that the fluid cartridge 120 may have a configuration other than that depicted in FIG. 2. For example, the fluid cartridge may have a different outer shape or a different reservoir volume. In another example, the fluid cartridge may comprise a reservoir that is integral with the pump housing structure 110 (e.g., the fluid cartridge can be defined by one or more walls of the pump housing structure 110 that surround a plunger to define a reservoir in which the medicine is injected or otherwise received).

In some embodiments, the pump device 100 may include one or more structures that interfere with the removal of the medicine cartridge 120 after the medicine cartridge 120 is inserted into the cavity 116. For example, as shown in FIG. 2, the pump housing structure 110 may include one or more retainer wings 119 that at least partially extend into the cavity 116 to engage a portion of the medicine cartridge 120 when the medicine cartridge 120 is installed therein. In this embodiment, the pump housing structure 110 includes a pair of opposing retainer wings 119 (only one is shown in the view in FIG. 2) that flex toward the inner surface of the cavity 116 during insertion of the medicine cartridge 120. After the medicine cartridge is inserted to a particular depth, the retainer wings 119 are biased to flex outward (toward the center of the cavity 116) so that the retainer wings 119 engage a neck portion 129 of the medicine cartridge 120. This engagement with the retainer wings 119 and the neck portion 129 hinder any attempts to remove the medicine cartridge 120 away from the pump device 100. Alternative embodiments can include other features and/or configurations to hinder the removal of the medicine cartridge 120.

Embodiments of the pump device 100 that hinder the removal of the medicine cartridge 120 may facilitate the “one-time-use” feature of the pump device 100. Because the retainer wings 119 can interfere with attempts to remove the medicine cartridge 120 from the pump device 100, the pump device 100 will be discarded along with the medicine cartridge 120 after the medicine cartridge 120 is emptied, expired, or otherwise exhausted. The retainer wings 119 may serve to hinder attempts to remove the exhausted medicine cartridge 120 and to insert a new medicine cartridge 120 into the previously used pump device 100. Accordingly, the pump device 100 may operate in a tamper-resistant and safe manner because the pump device 100 can be designed with predetermined life expectancy (e.g., the “one-time-use” feature in which the pump device is discarded after the medicine cartridge 120 is emptied, expired, or otherwise exhausted).

Still referring to FIGS. 1 and 2, the cap device 130 can be joined with the pump device 100 after the medicine cartridge is inserted in the cavity 116. It should be understood that the cap device 130 may supplement or replace the previously described retainer wings 119 by locking into position after joining with the pump housing 110, thereby hindering removal of the fluid cartridge 120 in the pump housing 110. As shown in FIGS. 1 and 2, the cap device 130 may include an output port 139 that connects with the tubing 72 for dispensation of the medicine to the user. In some embodiments, the output port 139 may have an angled orientation such that a portion of the tubing extends transversely to the central axis of the cartridge 120 and cap device 130. The output port 139 can be configured to mate with tubing 72 of the infusion set 70 (FIG. 1).

In some embodiments, the controller device 200 may be removably attached to the pump device 100 so that the two components are mechanically mounted to one another in a fixed relationship. Such a mechanical mounting can form an electrical connection between the removable controller device 200 and the pump device 100. For example, the controller device 200 may be in electrical communication with a portion of a drive system (described in connection with FIG. 10) of the pump device 100. As described in more detail below, the pump device 100 includes a drive system that causes controlled dispensation of the medicine or other fluid from the cartridge 120. In some embodiments, the drive system incrementally advances a piston rod longitudinally into the cartridge 120 so that the fluid is forced out of an output end 122. The septum 121 at the output end 122 of the fluid cartridge 120 can be pierced to permit fluid outflow when the cap device 130 is connected to the pump housing structure 110. Thus, when the pump device 100 and the controller device 200 are attached and thereby electrically connected, the controller device 200 communicates electronic control signals via a hardwire-connection (e.g., electrical contacts or the like) to the drive system or other components of the pump device 100. In response to the electrical control signals from the controller device 200, the drive system of the pump device 100 causes medicine to incrementally dispense from the medicine cartridge 120.

The controller device 200 may be configured to removably attach to the pump device 100, for example, in a side-by-side arrangement. The compact size permits the infusion pump assembly 60 to be discrete and portable when the pump device 100 is attached with the controller device 200 (as shown in FIG. 1). In this embodiment, the controller device 200 includes a controller housing structure 210 having a number of features 112/212 that are configured to mate with complementary features of the pump housing structure 110 so as to form a releasable mechanical connection (described below in more detail in connection with FIGS. 5-7). Such mating features 112/212 of the pump housing structure 110 and the controller housing structure 210 can provide a secure connection when the controller device 200 is attached to the pump device 100.

As shown in FIG. 2, the pump device 100 may include an electrical connector 118 (e.g., having conductive pads, pins, or the like) that are exposed to the controller device 200 and that mate with a complementary electrical connector (refer to connector 218 in FIG. 6) on the adjacent face of the controller device 200. The electrical connectors 118 and 218 provide the electrical communication between the control circuitry (refer, for example, to FIG. 9) housed in the controller device 200 and at least a portion of the drive system or other components of the pump device 100. In some exemplary embodiments, the electrical connectors 118 and 218 permit the transmission of electrical control signals to the pump device 100 and the reception of feedback signals (e.g., sensor signals) from particular components within the pump device 100. Furthermore, as described in more detail below, the infusion pump assembly 60 may include a gasket 140 that provides a seal which is resistant to migration of external contaminants when the pump device 100 is attached to the controller device 200. Thus, in some embodiments, the pump device 100 and the controller device 200 can be assembled into a water resistant configuration that protects the electrical interconnection from water migration (e.g., if the user encounters water while carrying the pump assembly 60).

Referring again to FIGS. 1 and 2, the controller device 200 includes the user interface 220 that permits a user to monitor the operation of the pump device 100. In some embodiments, the user interface 220 includes a display 222 and one or more user-selectable buttons (e.g., four buttons 224a, 224b, 224c, and 224d in this embodiment). The display 222 may include an active area in which numerals, text, symbols, images, or a combination thereof can be displayed (refer, for example, to FIG. 2). For example, the display 222 may be used to communicate a number of status indicators, alarms, settings, and/or menu options for the infusion pump system 10. In some embodiments, the display 222 can indicate the user's blood glucose level, an indication that the user's blood glucose level is rising or falling, and the TIL information. In the example depicted in FIG. 1, the TIL information shown in the display 222 is “2.2 U,” which indicates that approximately 2.2 units of dispensed insulin (including previous basal and bolus dosages) has yet to act on the user's blood glucose level (in particular embodiments, after accounting for any previously consumed food that has not yet been metabolized). In this embodiment, the display 222 also indicates that the user's blood glucose level is currently at 180 mg/dl and is falling.

In some embodiments, the user may press one or more of the buttons 224a, 224b, 224c, and 224d to shuffle through a number of menus or program screens that show particular status indicators, settings, and/or data (e.g., review data that shows the medicine dispensing rate, the total amount of medicine dispensed in a given time period, the amount of medicine scheduled to be dispensed at a particular time or date, the approximate amount of medicine remaining in the cartridge 120, or the like). In some embodiments, the user can adjust the settings or otherwise program the controller device 200 by pressing one or more buttons 224a, 224b, 224c, and 224d of the user interface 220. For example, in embodiments of the infusion pump system 10 configured to dispense insulin, the user may press one or more of the buttons 224a, 224b, 224c, and 224d to change the dispensation rate of insulin or to request that a bolus of insulin be dispensed immediately or at a scheduled, later time.

The display 222 of the user interface 220 may be configured to display quick reference information when no buttons 224a, 224b, 224c, and 224d have been pressed. For example, as shown in FIG. 2, the active area of the display 222 can display the time (10:30 AM in this example), blood glucose level (118 mg/dl in this example), an indication of whether the user's blood glucose level is rising or falling (the upward arrow indicates a rising glucose level in this example), and the user's current TIL information (a 10% load in this example, which represents a normalized value of the TIL calculation as described below in connection with FIGS. 13-16B). This information can be displayed for a period of time after no button 224a, 224b, 224c, and 224d has been actuated (e.g., five seconds, 10 seconds, 30 seconds, 1 minute, 5 minutes, or the like). Thereafter, the display 222 may enter sleep mode in which the active area is blank, thereby conserving battery power. In addition or in the alternative, the active area can display particular device settings, such as the current dispensation rate or the total medicine dispensed, for a period of time after no button 224a, 224b, 224c, or 224d has been actuated (e.g., five seconds, 10 seconds, 30 seconds, 1 minute, 5 minutes, or the like). Again, thereafter the display 222 may enter sleep mode to conserve battery power. In certain embodiments, the display 222 can dim after a first period of time in which no button 224a, 224b, 224c, or 224d has been actuated (e.g., after 15 seconds or the like), and then the display 222 can enter sleep mode and become blank after a second period of time in which no button 224a, 224b, 224c, or 224d has been actuated (e.g., after 30 seconds or the like). Thus, the dimming of the display device 222 can alert a user viewing the display device 222 when the active area 223 of the display device will soon become blank.

Accordingly, when the controller device 200 is connected to the pump device 100, the user is provided with the opportunity to readily monitor infusion pump operation by simply viewing the display 222 of the controller device 200. Such monitoring capabilities may provide comfort to a user who may have urgent questions about the current operation of the pump device 100 (e.g., the user may be unable to receive immediate answers if wearing an infusion pump device having no user interface attached thereto). Moreover, the TIL information can be displayed contemporaneously with the detected blood glucose value, so the user is provided with the opportunity to make informed decisions regarding the current and future status of his or her blood glucose level.

Also, in these embodiments, there may be no need for the user to carry and operate a separate module to monitor the operation of the infusion pump device 100, thereby simplifying the monitoring process and reducing the number of devices that must be carried by the user. If a need arises in which the user desires to monitor the operation of the pump device 100 or to adjust settings of the infusion pump system 10 (e.g., to request a bolus amount of medicine), the user can readily operate the user interface 220 of the controller device 200 without the requirement of locating and operating a separate monitoring module.

In other embodiments, the user interface controller device 200 is not limited to the display and buttons depicted in FIGS. 1 and 2. For example, in some embodiments, the user interface 220 may include only one button or may include a greater numbers of buttons, such as two buttons three buttons, four buttons, five buttons, or more. In another example, the user interface 220 of the controller device 200 may include a touch screen so that a user may select buttons defined by the active area of the touch screen display. Alternatively, the user interface 220 may comprise audio inputs or outputs so that a user can monitor the operation of the pump device 100.

Referring to FIGS. 3 and 4, the infusion pump system 10 may be configured to be portable and can be wearable and concealable. For example, a user can conveniently wear the infusion pump assembly 60 on the user's skin (e.g., skin adhesive) underneath the user's clothing or carry the pump assembly 60 in the user's pocket (or other portable location) while receiving the medicine dispensed from the pump device 100. The pump device 100 may be arranged in a compact manner so that the pump device 100 has a reduced length. For example, in the circumstances in which the medicine cartridge 120 has a length of about 7 cm or less, about 6 cm to about 7 cm, and about 6.4 cm in one embodiment, the overall length of the pump housing structure 110 (which contains medicine cartridge and the drive system) can be about 10 cm or less, about 7 cm to about 9 cm, and about 8.3 cm in one embodiment. In such circumstances, the controller device 200 can be figured to mate with the pump housing 110 so that, when removably attached to one another, the components define a portable infusion pump system that stores a relatively large quantity of medicine compared to the overall size of the unit. For example, in this embodiment, the infusion pump assembly 60 (including the removable controller device 200 attached to the pump device 100 having the cap device 130) may have an overall length of about 11 cm or less, about 7 cm to about 10 cm, and about 9.6 cm in one embodiment; an overall height of about 6 cm or less, about 2 cm to about 5 cm, and about 4.3 cm in one embodiment; and an overall thickness of about 20 mm or less, about 8 mm to about 20 mm, and about 18.3 mm in one embodiment.

The infusion pump system 10 is shown in FIGS. 3 and 4 is compact so that the user can wear the portable infusion pump system 10 (e.g., in the user's pocket, connected to a belt clip, adhered to the user's skin, or the like) without the need for carrying and operating a separate module. In such embodiments, the cap device 130 of the pump device 100 may be configured to mate with the infusion set 70. In general, the infusion set 70 is tubing system that connects the infusion pump system 10 to the tissue or vasculature of the user (e.g., to deliver medicine into the user's subcutaneous tissue or vasculature). The infusion set 70 may include the flexible tube 72 that extends from the pump device 100 to the subcutaneous cannula 76 retained by a skin adhesive patch 78 that secures the subcutaneous cannula 76 to the infusion site. The skin adhesive patch 78 can retain the infusion cannula 76 in fluid communication with the tissue or vasculature of the patient so that the medicine dispensed through the tube 72 passes through the cannula 76 and into the user's body. The cap device 130 may provide fluid communication between the output end 122 (FIG. 2) of the medicine cartridge 120 and the tube 72 of the infusion set 70. For example, the tube 72 may be directly connected to the output port 139 (FIG. 2) of the cap device 130. In another example, the infusion set 70 may include a connector (e.g., a Luer connector or the like) attached to the tube 72, and the connector can then mate with the cap device 130 to provide the fluid communication to the tube 72. In these examples, the user can carry the portable infusion pump assembly 60 (e.g., in the user's pocket, connected to a belt clip, adhered to the user's skin, or the like) while the tube 72 extends to the location in which the skin is penetrated for infusion. If the user desires to monitor the operation of the pump device 100 or to adjust the settings of the infusion pump system 10, the user can readily access the user interface 220 of the controller device 200 without the need for carrying and operating a separate module.

Referring to FIG. 3, in some embodiments, the infusion pump assembly 60 is pocket-sized so that the pump device 100 and controller device 200 can be worn in the user's pocket 6 or in another portion of the user's clothing. For example, the pump device 100 and the controller device 200 can be attached together and form the pump assembly 60 that comfortably fits into a user's pocket 6. The user can carry the portable infusion pump assembly 60 and use the tube 72 of the infusion set 70 to direct the dispensed medicine to the desired infusion site. In some circumstances, the user may desire to wear the pump assembly 60 in a more discrete manner. Accordingly, the user may pass the tube 72 from the user's pocket 6, under the user's clothing, and to the infusion site where the adhesive patch 78 is positioned. As such, the infusion pump system 10 can be used to deliver medicine to the tissues or vasculature of the user in a portable, concealable, and discrete manner. Furthermore, the monitoring device 50 can be worn on the user's skin while the pump assembly 60 is carried by the user (e.g., in a pocket). As such, the monitoring device 50 can communicate information indicative of the user's blood glucose level to the pump assembly 60 while the pump assembly 60 is used to deliver medicine through the infusion set 70. In this embodiment, the monitoring device 50 may be arranged on the user's skin at a location that is spaced apart from the infusion set 70.

Referring to FIG. 4, in other embodiments, the infusion pump assembly 60 may be configured to adhere to the user's skin 7 directly at the location in which the skin is penetrated for medicine infusion. For example, a rear surface of the pump device 100 may include a skin adhesive patch so that the pump device 100 is physically adhered to the skin of the user at a particular location. In these embodiments, the cap device 130 may have a configuration in which medicine passes directly from the cap device 130 into an infusion cannula 76 that is penetrated into the user's skin. In one example, the fluid output port 139 through the cap device 130 can include a curve or a 90° corner so that the medicine flow path extends longitudinally out of the medicine cartridge and thereafter laterally toward the user's skin 7. Again, if the user desires to monitor the operation of the pump device 100 or to adjust the settings of the infusion pump system 10, the user can readily access the user interface 220 of the controller device 200 without the need for carrying and operating a second, separate device. For example, the user may look toward the pump device 100 to view the user interface 220 of the controller device 200 that is removably attached thereto. In another example, the user can temporarily detach the controller device 200 (while the pump device 100 remains adhered to the user's skin 7) so as to view and interact with the user interface 220. Furthermore, the monitoring device 50 can be worn on the user's skin while the pump assembly 60 is worn on the user's skin in a different location from that where the monitoring device is worn. As such, the monitoring device 50 can communicate information indicative of the user's blood glucose level to the pump assembly 60 while the pump assembly 60 is used to deliver medicine through the infusion set 70. In this embodiment, the monitoring device 50 may be arranged on the user's skin at a location that is spaced apart from the infusion set 70.

In the embodiments depicted in FIGS. 3 and 4, the monitoring device 50 adheres to the user's skin 7 at the location in which the skin is penetrated by the sensor shaft 56 (to detect blood glucose levels). The sensor shaft 56 (refer to FIG. 1) penetrates the skin surface for the purpose of exposing the tip portion of the sensor shaft 56 to the tissue or the vasculature of the user. The sensor shaft 56 can detect information indicative of the user's blood glucose level and transfer this information to a circuit that is connected to the communications device 54 located within the monitoring device 50. The communication device 54 can be in wireless communication with the communication device 247 (described in connection with FIG. 9) included in the controller device 200 of the pump assembly 60.

Referring now to FIGS. 5-8, in some embodiments, the infusion pump assembly 60 can be operated such that the pump device 100 is a disposable, non-reusable component while the controller device 200 is a reusable component. In these circumstances, the pump device 100 may be configured as a “one-time-use” device that is discarded after the medicine cartridge is emptied, expired, or otherwise exhausted. Thus, in some embodiments, the pump device 100 may be designed to have an expected operational life of about 1 day to about 30 days, about 1 day to about 20 days, about 1 to about 14 days, or about 1 day to about 7 days depending on the volume of medicine in the cartridge 120, the dispensation patterns that are selected for the individual user, and other factors. For example, in some embodiments, the medicine cartridge 120 containing insulin may have an expected usage life about 7 days after the cartridge is removed from a refrigerated state and the septum 121 (FIG. 2) is punctured. In some circumstances, the dispensation pattern selected by the user can cause the insulin to be emptied from the medicine cartridge 120 before the 7-day period. If the insulin is not emptied from the medicine cartridge 120 after the 7-day period, the remaining insulin may become expired sometime thereafter. In either case, the pump device 100 and the medicine cartridge 120 therein can be discarded after exhaustion of the medicine cartridge 120 (e.g., after being emptied, expired, or otherwise not available for use).

The controller device 200, however, may be reused with subsequent new pump devices 100′ and new medicine cartridges 120′. As such, the control circuitry, the user interface components, and other components that may have relatively higher manufacturing costs can be reused over a longer period of time. For example, in some embodiments, the controller device 200 may be designed to have an expected operational life of about 1 year to about 7 years, about 2 years to about 6 years, or about 3 years to about 5 years—depending on a number of factors including the usage conditions for the individual user. Accordingly, the user is permitted to reuse the controller device 200 (which may include complex or valuable electronics) while disposing of the relatively low-cost pump device 100 after each use. Such an infusion pump system 10 can provide enhanced user safety as a new pump device 100′ (and drive system therein) is employed with each new fluid cartridge 120.

Referring to FIGS. 5 and 6, the pump device 100 can be readily removed from the controller device 200 when the medicine cartridge 120 is exhausted. As previously described, the medicine cartridge 120 is arranged in the cavity 116 (FIG. 2) of the pump housing 110 where it is retained by the cap device 130. In some embodiments, a portion of the pump housing 110 can comprise a transparent or translucent material so that at least a portion of the medicine cartridge 120 is viewable therethrough. For example, the user may want to visually inspect the medicine cartridge when the plunger 125 is approaching the output end 122 of the medicine cartridge, thereby providing a visual indication that the medicine cartridge may be emptied in the near future. In this embodiment, the barrel 111 of the pump housing 110 comprises a generally transparent polymer material so that the user can view the medicine cartridge 120 to determine if the plunger 125 is nearing the end of its travel length.

As shown in FIG. 5, the pump device 100 has been used to a point at which the medicine cartridge 120 is exhausted. The plunger 125 has been advanced, toward the left in FIG. 5, over a period of time so that all or most of the medicine has been dispensed from the cartridge 120. In some embodiments, the controller device 200 may provide a visual or audible alert when this occurs so as to remind the user that a new medicine cartridge is needed. In addition or in the alternative, the user may visually inspect the medicine cartridge 120 through the barrel 111 of the pump housing 110 to determine if the medicine cartridge 120 is almost empty. When the user determines that a new medicine cartridge 120 should be employed, the pump device 100 can be readily separated from the controller device 200 by actuating a release member 215. In this embodiment, the release member 215 is a latch on the controller device 200 that is biased toward a locking position to engage the pump device 100. The latch may be arranged to engage one or more features on a lateral side of the pump housing 110. As such, the user may actuate the release member 215 by moving the release member 215 in a lateral direction 216 (FIG. 5) away from the pump device 100 (e.g., by applying a force with the user's finger).

As shown in FIG. 6, when the release member 215 is actuated and moved to a position away from the pump device 100, a segmented guide rail 114a, 114b, 114c is free to slide longitudinally in a guide channel 214a, 214b without interference from the release member 215. Accordingly, the user can move the pump device 100 in a longitudinal direction 217 away from the controller device 200. For example, the segmented guide rail 114a, 114b, 114c may slide along the guide channel 214a, 214b, the extension 113 (FIG. 2) may be withdrawn from the mating depression 213 (FIG. 6), and the electrical connector 118 can be separated from the mating connector 218. In these circumstances, the pump device 100 is physically and electrically disconnected from the controller device 200 while the pump device retains the exhausted medicine cartridge 120. It should be understood that, in other embodiments, other features or connector devices can be used to facilitate the side-by-side mounting arrangement. These other features or connector devices may include, for example, magnetic attachment devices, mating tongues and grooves, or the like.

In some embodiments, the gasket 140 compressed between the pump device 100 and the controller device 200 may comprise a resilient material. In such circumstances, the gasket 140 can provide a spring-action that urges the pump device 100 to shift a small amount away from the controller device 200 when the release member 215 is moved to the unlocked position (e.g., moved in the lateral direction 216 in the embodiment shown in FIG. 5). Accordingly, in some embodiments, the pump device 100 can automatically and sharply move a small distance (e.g., about 0.5 mm to about 5 mm) away from the controller device 200 when the release member 215 is moved to the unlocked position. Such an automatic separation provides a convenient start for the user to detach the pump device 100 away from the controller device 200. Furthermore, this automatic separation caused by the spring-action of the gasket 140 can provide a swift disconnect between the electrical connectors 118 and 218 when the pump device 100 is being replaced.

Referring to FIGS. 7 and 8, the same controller device 200 can be reused with a new pump device 100′ having a new medicine cartridge 120′ retained therein, and the previously used pump device 100 can be discarded with the exhausted medicine cartridge 120. The new pump device 100′ (FIG. 7) can have a similar appearance, form factor, and operation as the previously used pump device 100 (FIGS. 5 and 6), and thus the new pump device 100′ can be readily attached to the controller device 200 for controlled dispensation of medicine from the new medicine cartridge 120′. In some embodiments, the user may prepare the new pump device 100′ for use with the controller device 200. For example, the user may insert the new medicine cartridge 120′ in the cavity 116 of the new pump device 100′ and then join the cap device 130 to the pump housing to retain the new medicine cartridge 120′ therein (refer, for example, to FIG. 2). Although the tubing 72 of the infusion set 70 is not shown in FIG. 7, it should be understood that the tubing 72 may be attached to the cap device 130 prior to the cap device 130 being joined with the pump housing 110. For example, a new infusion set 70 can be connected to the cap device 130 so that the tubing 72 can be primed (e.g., a selected function of the pump device 100 controlled by the controller device 200) before attaching the infusion set patch to the user's skin. As shown in FIG. 7, the new medicine cartridge 120′ may be filled with medicine such that the plunger 125 is not viewable through the barrel 111. In some embodiments, the user can removably attach the pump device 100 to the controller device 200 by moving the pump device 100 in a longitudinal direction 219 toward the controller device 200 such that the segmented guide rail 114a, 114b engages and slides within the guide channel 214a, 214b. When the electrical connectors 118 and 218 mate with one another, the release member 215 can engage the segmented guide rails 114a, 114b to retain the pump device 100 with the controller device 200.

As shown in FIG. 8, the previously used pump device 100 that was separated from the controller device (as described in connection with FIGS. 5 and 6) may be discarded after a single use. In these circumstances, the pump device 100 may be configured as a disposable “one-time-use” device that is discarded by the user after the medicine cartridge 120 is emptied, is expired, has ended its useful life, or is otherwise exhausted. For example, the pump device 100 may be discarded into a bin 30, which may include a trash bin or a bin specifically designated for discarded medical products. Thus, the user is permitted to dispose of the relatively low-cost pump device 100 after each use while reusing the controller device 200 (which may include complex or valuable electronics) with subsequent new pump devices 100′. Also, in some circumstances, the infusion set 70 (not shown in FIG. 8, refer to FIG. 1) that was used with the pump device 100 may be removed from the user and discarded into the bin 30 along with the pump device 100. Alternatively, the infusion set 70 can be disconnected from the previous pump device 100 and attached to the new pump device 100′. In these circumstances, the user may detach the infusion set cannula 76 and patch 78 from the skin so as to “re-prime” the tubing with medicine from the new pump device 100′ to remove air pockets from the tubing. Thereafter, the infusion set cannula 76 and patch 78 can be again secured to the user's skin.

Referring now to FIG. 9, the controller device 200 (shown in an exploded view) houses a number of components that can be reused with a series of successive pump devices 100. In particular, the controller device 200 includes control circuitry 240 arranged in the controller housing 210 that is configured to communicate control signals to the drive system of the pump device 100. In this embodiment, the control circuitry 240 includes a main processor board 242 that is in communication with a power supply board 244. The control circuitry 240 includes at least one processor 243 that coordinates the electrical communication to and from the controller device 200 (e.g., communication between the controller device 200 and the pump device 100). The processor 243 can be arranged on the main processor board 242 along with a number of other electrical components such as memory devices (e.g., memory chip 248). It should be understood that, although the main processor board 242 is depicted as a printed circuit board, the main processor board can have other forms, including multiple boards, a flexible circuit substrate, and other configurations that permit the processor 243 to operate. The control circuitry 240 can be programmable in that the user may provide one or more instructions to adjust a number of settings for the operation of the infusion pump system 10. Such settings may be stored in the one or more memory devices, such as the memory chip 248 on the processor board 242. The control circuitry 240 may include other components, such as sensors (e.g., occlusion sensors), that are electrically connected to the main processor board 242. Furthermore, the control circuitry 240 may include one or more dedicated memory devices that store executable software instructions for the processor 243. The one or more memory devices (e.g., the memory chip 248) can also store information related to a user's blood glucose level and total insulin load (described in more detail in association with FIGS. 11-19) over a period of time.

As previously described, the controller device 200 can be electrically connected with the pump device 100 via mating connectors 118 and 218 so that the control circuitry 240 can communicate control signals to the pump device 100 and receive feedback signals from components housed in the pump device 100. In this embodiment, the electrical connector 118 (FIG. 2) on the pump device 100 is a z-axis connector, and the connector 218 (FIG. 6) on the controller device 200 is adapted to mate therewith. The electrical connector 218 on the controller device 200 is in communication with the control circuitry 240. As such, the processor 243 can operate according to software instructions stored in the memory device so as to send control signals to the pump device 100 via the connector 218.

Still referring to FIG. 9, the user interface 220 of the controller device 200 can include input components, output components, or both that are electrically connected to the control circuitry 240. For example, in this embodiment, the user interface 220 includes a display device 222 having an active area that outputs information to a user and four buttons 224a-d that receive input from the user. Here, the display 222 may be used to communicate a number of status indicators, settings, and/or menu options for the infusion pump system 10. In some embodiments, the control circuitry 240 may receive the input commands from the user's button selections and thereby cause the display device 222 to output a number of status indicators (e.g., if the infusion pump system 10 is delivering insulin and/or if the user's blood glucose level is rising or falling), menus, and/or program screens that show particular settings and data (e.g., review data that shows the medicine dispensing rate, the total amount of medicine dispensed in a given time period, the amount of medicine scheduled to be dispensed at a particular time or date, the approximate amount of medicine remaining the cartridge 120, the user's total insulin load, or the like). As previously described, the controller circuitry 240 can be programmable in that the input commands from the button selections can cause the controller circuitry 240 to change any one of a number of settings for the infusion pump device 100.

Some embodiments of the control circuitry 240 may include a cable connector (e.g., a USB connection port, another data cable port, or a data cable connection via the electrical connector 218) that is accessible on an external portion of the controller housing 210. As such, a cable may be connected to the control circuitry 240 to upload data or program settings to the controller circuit or to download data from the control circuitry 240. For example, historical data of blood glucose level, medicine delivery, and/or TIL information can be downloaded from the control circuitry 240 (via the cable connector) to a computer system of a physician or a user for purposes of analysis and program adjustments (refer, for example, to FIG. 18). Optionally, the data cable may also provide recharging power.

Referring to FIGS. 9 and 10, the control circuitry 240 of the controller device 200 may include a second power source 245 (FIG. 9) that can receive electrical energy from a first power source 345 (FIG. 10) housed in the pump device 100. In this embodiment, the second power source 245 is coupled to the power supply board 244 of the control circuitry 240. The hard-wired transmission of the electrical energy can occur through the previously described connectors 118 and 218. In such circumstances, the first power source 345 may include a high density battery that is capable of providing a relatively large amount of electrical energy for its package size, while the second power source 245 may include a high current-output battery that is capable discharging a brief current burst to power the drive system 300 of the pump device 100. Accordingly, the first battery 345 disposed in the pump device 100 can be used to deliver electrical energy over time (e.g., “trickle charge”) to the second battery 245 when the controller device 200 is removably attached to the pump device 100. For example, the first battery 345 may comprise a zinc-air cell battery. The zinc-air cell battery 345 may have a large volumetric energy density compared to some other battery types. Also, the zinc-air cell battery may have a long storage life, especially in those embodiments in which the battery is sealed (e.g., by a removable seal tab or the like) during storage and before activation.

The second battery 245 may include a high current-output device that is housed inside the controller housing 210. The second battery 245 can be charged over a period of time by the first battery 345 and then intermittently deliver bursts of high-current output to the drive system 300 over a brief moment of time. For example, the second battery 245 may comprise a lithium-polymer battery. The lithium-polymer battery 245 disposed in the controller device 200 may have an initial current output that is greater than the zinc-air cell battery 345 disposed in the pump device 100, but zinc-air cell battery 345 may have an energy density that is greater than the lithium-polymer battery 245. In addition, the lithium-polymer battery 245 is readily rechargeable, which permits the zinc-air battery 345 disposed in the pump device 100 to provide electrical energy to the lithium-polymer battery 245 for purposes of recharging. In alternative embodiments, it should be understood that the second power source 245 may comprise a capacitor device capable of being recharged over time and intermittently discharging a current burst to activate the drive system 300.

Accordingly, the infusion pump system 10 having two power sources 345 and 245 one arranged in the pump device 100 and another arranged in the reusable controller device 200 permits a user to continually operate the controller device 200 without having to recharge a battery via an outlet plug-in or other power cable. Because the controller device 200 can be reusable with a number of pump devices 100 (e.g., attach the new pump device 100′ after the previous pump device 100 is expended and disposed), the second power source 245 in the controller device can be recharged over a period of time each time a new pump device 100 is connected thereto. Such a configuration can be advantageous in those embodiments in which the pump device 100 is configured to be a disposable, one-time-use device that attaches to a reusable controller device 200. For example, in those embodiments, the “disposable” pump devices 100 recharge the second power source 245 in the “reusable” controller device 200, thereby reducing or possibly eliminating the need for separate recharging of the controller device 200 via a power cord plugged into a wall outlet.

Referring now to FIG. 10, the pump device 100 in this embodiment includes the drive system 300 that is controlled by the removable controller device 200 (see FIG. 2). Accordingly, the drive system 300 can accurately and incrementally dispense fluid from the pump device 100 in a controlled manner. The drive system 300 may include a flexible piston rod 370 that is incrementally advanced toward the medicine cartridge 120 so as to dispense the medicine from the pump device 100. At least a portion of the drive system 300 is mounted, in this embodiment, to the pump housing 110. Some embodiments of the drive system 300 may include a battery powered actuator (e.g., reversible motor 320 or the like) that actuates a gear system 330 to reset a ratchet mechanism (e.g., including a ratchet wheel and pawl), a spring device (not shown) that provides the driving force to incrementally advance the ratchet mechanism, and a drive wheel 360 that is rotated by the ratchet mechanism to advance the flexible piston rod 370 toward the medicine cartridge 120. Connected to piston rod 370 is a plunger engagement device 375 for moving the plunger 125 of the medicine cartridge 120.

Some embodiments of the drive system 300 can include a pressure sensor 380 disposed between the plunger engagement device 375 and the plunger 125 for determining the pressure within the fluid path (e.g., inside the medicine cartridge 120, the infusion set 70, and the like). For example, the fluid pressure in the medicine cartridge 120 can act upon the plunger 125, which in turn can act upon the pressure sensor 380 arranged on the dry side of the plunger 125. The pressure sensor 380 may comprise a pressure transducer that is electrically connected (via one or more wires) to a gateway circuit 318 so that the sensor signals can be communicated to the controller device 200 (e.g., via the electrical connectors 118 and 218). As such, data from the pressure sensor 380 can be received by the controller device 200 for use with, for example, an occlusion detection module to determine if an occlusion exists in the medicine flow path. Alternatively, the controller device 200 may include an optical sensor system (not shown in FIGS. 9 and 10) to detect occlusions in the fluid path. For example, a light emitter and light sensor may each be arranged on a sensor circuit in the controller device 200 (but aligned with the pump device 100) so that the light sensor can detect the amount of light emitted by the light emitter and subsequently reflected from a component adjacent the fluid path. The reflected light level detected may be used to determine the pressure within the fluid path.

Referring now to FIG. 11, the infusion pump system 10 can be used to determine a user's TIL at a particular point in time. For example, a process 400 for determining TIL information can be implemented by the controller device 200. As previously described, the pump assembly 60 can operate to deliver insulin to the user by basal dosages, selected bolus dosages, or a combination thereof. A basal rate of insulin can be delivered in an incremental manner (e.g., dispense 0.25 U every fifteen minutes for a rate of 1.0 U per hour) to help maintain the user's blood glucose level within a targeted range during normal activity when the user is not eating or otherwise consuming food items. The user may select one or more bolus deliveries, for example, to offset the blood glucose effects caused by the intake of food or to correct for an undesirably high blood glucose level. In some circumstances, the basal rate pattern may be programmed by a health care professional during a clinical visit (or, optionally, by the user) and may remain at a substantially constant rate for a long period of time (e.g., a first basal dispensation rate for a period of hours in the morning, and a second basal dispensation rate for a period of hours in the afternoon and evening). In contrast, the bolus dosages can be dispensed in user-selected amounts based on calculations made by the controller device 200. For example, the controller device 200 can be informed of a high glucose level (e.g., by user input, data received from the glucose monitoring device 50, or the like) and can make a suggestion to the user to administer a bolus of insulin to correct for the high blood glucose reading. In another example, the user can request that the controller device 200 calculate and suggest a bolus dosage based, at least in part, on a proposed meal that the user plans to consume.

The basal and bolus insulin dispensed into the user's system may act over a period of time to control the user's blood glucose level. As such, the user's body may include some amount of insulin that has not yet acted even while the infusion pump assembly 60 is activated to deliver additional dosages (basal, bolus, or both). In these circumstances, the controller device 200 may implement a process 400 (FIG. 11) to determine the user's total insulin load (TIL), which can provide an accurate indication of the previously dispensed insulin (both basal and bolus dosages) which has not yet acted in the user's body. The TIL information can be determined in a manner that accounts for the substantial delay between the time that insulin is delivered to the tissue of the subcutaneous region and the time that this insulin reaches the blood supply. For example, the delay between a subcutaneous delivery of a bolus dosage of insulin and the peak plasma insulin level achieved from this bolus can be one hour or more. Additionally, the bolus dosage may not enter the blood stream all at once. As such, the effect of the bolus can peak at about one to two hours and then decay in a predictable manner over as much as eight hours or more (described in more detail in connection with FIG. 12). Due to the time decay effects of insulin activity, the user could be susceptible to request a subsequent bolus dosage while some insulin from a previously delivered bolus dosage has not yet acted upon the user (a scenario sometimes referred to as “bolus stacking”). To reduce the likelihood of undesirable bolus stacking, the TIL information can be determined by the controller device 200 on a periodic basis so that the user can be aware of the previously dispensed insulin which has not yet acted in the user's body. As described in more detail below, the TIL information can also be used in a bolus suggestion feature of the controller device 200 so that the suggested bolus amount accounts for the previously dispensed insulin (both basal and bolus dosages) which has not yet acted in the user's body.

For diabetics, their long term health may depend greatly on the ability to accurately control their blood glucose levels under a wide variety of conditions and to quickly and accurately respond to changes in blood glucose level from, for example, changes in activity level, carbohydrate ingestion, or the like. As such, it can be beneficial for a user to employ the infusion pump system 10 that enables the user to make well-informed decisions about future insulin boluses and basal rates. For example, the controller device 200 can readily indicate to the user his or her current TIL information, which is generally more accurate than other insulin estimation tools that are based on bolus dosages alone. Also, the controller device 200 can be used to suggest future bolus amounts based upon (1) actual and target blood glucose levels, (2) proposed food items to be consumed, and (3) the TIL information determined in a manner that accounts for both the previous bolus deliveries and the previous basal deliveries and (optionally) the user's previously consumed carbohydrates that have not yet been metabolized.

Referring in more detail to the illustrative process 400 shown in FIG. 11, the process 400 for the determining of the TIL of a user can include a number of operations performed by the controller device 200. In operation 405, the controller device 200 can initiate a TIL calculation for a particular time t_nbased on, for example, a request by the user (e.g., on-demand calculation) or a controller routine that determines the TIL information on a periodic basis (e.g., every 1 minute, every 2 minutes, every 5 minutes, every 10 minutes, every 30 minutes, or the like). In some embodiments, the TIL value can be calculated based on two or (optionally) three components: a bolus insulin load component, a basal insulin load component, and (optionally) a previous food component.

In operation 410, the controller device 200 can determine the bolus insulin load at time t_nbased on bolus dosages that have been delivered to the patient in the recent past. In some embodiments, for each bolus dosage dispensed within a predetermined period of time before t_n(e.g., 6 hours, 7 hours, 7.5 hours, 8 hours, 10 hours, or the like), the controller device 200 can estimate the amount of bolus insulin that has not yet acted in the blood stream from time-decay models generated from pharmacodynamic data of the insulin. For example, a graph of an exemplary curve depicting the percent of insulin remaining versus time can be seen in FIG. 12. In particular, FIG. 12 illustrates an example of the insulin action curve generated from pharmacodynamic data for the insulin stored in the cartridge 120. Thus, in this embodiment, the bolus insulin load component of the TIL calculation represents the sum of all recent bolus insulin dosages wherein each bolus insulin dosage is discounted by the active insulin function (which may be modeled on pharmacodynamic data as shown, for example, in FIG. 12).

Still referring to FIG. 11, in operation 415, the controller device 200 can determine the basal insulin load at time t_nbased on, for example, the previous basal rate during a predetermined period of time (e.g., 6 hours, 7 hours, 7.5 hours, 8 hours, 10 hours, or the like). For each basal insulin dispensation (e.g., 0.25 U dispensed every fifteen minutes, 0.5 U dispensed every fifteen minutes, 0.4 U dispensed every ten minutes, of the like), the controller device 200 can estimate the amount of basal insulin that has not yet acted in the blood stream from time-decay models generated from pharmacodynamic data of the insulin. As previously described, FIG. 12 illustrates an example of the insulin action curve generated from pharmacodynamic data for the insulin stored in the cartridge 120. Thus, in this embodiment, the basal insulin load component of the TIL calculation represents the sum of all recent basal insulin dosages wherein each basal insulin dosage is discounted by the active insulin function (which may be modeled on pharmacodynamic data as shown, for example, in FIG. 12). As described below in connection with FIG. 13, the basal insulin load at time t_nmay approach a constant value if the basal dosage rate remains constant over an extended period of time.

Optionally, the process 400 may include operation 420 in which the previous food component is employed in the TIL calculation. The controller device 200 can determine the previous food component based on, for example, the total carbohydrates previously entered into the controller device 200 as being consumed by the user during a predetermined period of time before t_n(e.g., 6 hours, 7 hours, 7.5 hours, 8 hours, 10 hours, or the like). The previous food component can be determined, for example, by estimating the amount of carbohydrates that have been consumed but not yet metabolized by the user's body so as to effect the blood glucose level. For each of the previous food items reported by the user, the controller device 200 can estimate the previously consumed food that has not yet been metabolized from a time-based model generated from a standard glycemic index. Alternatively, when the user enters information regarding food intake, the user can be prompted to identify the metabolization “speed” of the food item based on the glycemic index for that food. In these circumstances, the user may be prompted to input the amount of food (e.g., grams of Carbohydrate or another representative value) and then identify the glycemic index (via a numerical scale or from a list of two or more choices (e.g., “fast” metabolization and “slow” metabolization)) to provide a more accurate time-based function for specific meals. When this yet-to-be-metabolized carbohydrate value is estimated, it can be treated as a “negative” insulin component in the TIL calculation by multiplying the yet-to-be-metabolized carbohydrate value by a carbohydrate ratio (e.g., 1 unit of insulin per 15 grams of carbohydrates). In some embodiments, the calculated value for the previous food component can be displayed separately to the user (e.g., to provide the user with information regarding the effects of the previously consumed carbohydrates).

Still referring to FIG. 11, in operation 425, the TIL at time t_ncan be calculated by summing the bolus insulin load, the basal insulin load, and (in some embodiments) the previously consumed food component, where the previous food component is treated as a negative insulin unit value. In these circumstances, the TIL values may accurately reflect both the previously dispensed insulin that has not yet acted (to reduce or otherwise effect the blood glucose level) and the previously consumed food that has not yet been metabolized (to increase or otherwise effect the blood glucose level). It should be understood from the description herein that, in alternative embodiments, the process for determining the TIL information may not include the previous food component (as described in connection with operation 420). In such embodiments, the TIL at time t_ncan be calculated by summing both the bolus insulin load and the basal insulin load. Because this TIL determination is not based merely on previous bolus deliveries, the TIL information may accurately reflect basal rate changes and the impact of stopping insulin delivery or changing insulin delivery (e.g., a temporary basal rate adjustment).

In operation 430, the TIL value can be stored in the memory of the controller device 200 (e.g., in the memory chip 248 or in another memory device coupled to the control circuitry 240). For example, the calculated TIL value at time t_ncan be stored in a database along with the time t_n. The database may also store the current blood glucose level at time t_n, which may be generated from the sensor signal received from the monitoring device 50 (FIG. 1). As described in more detail below, the database can maintain a historical record of the TIL information, the time information, and (optionally) the detected blood glucose information that is accessible by the controller device 200 or by an external computer. In addition or in the alternative, the controller device 200 can be configured to perform an on-demand calculation of the TIL value as a function of recent history by storing each input data point (e.g., basal insulin dosages, bolus insulin dosages, food intake data, etc.) and then summing each component (e.g., the basal insulin load, the bolus insulin load, and the previously consumed food component) as a function of time.

In operation 435, the TIL information can be displayed on the user interface 220 of the pump controller device 200. The TIL information can be retrieved from the memory device that stores the recently calculated TIL value. In particular embodiments, the display 222 of the user interface 220 may be configured to display a default reference information screen when the user is not activating any menu screens (e.g., a reference screen that is displayed after no buttons are pressed for a period of time). For example, as shown in FIG. 1, the display 222 can indicate the time (10:30 AM in this example), the date (January 1 in this example), the user's current blood glucose level (180 mg/dl in this example), an indication of whether the user's blood glucose level is rising or falling (the downward arrow indicates a decreasing glucose level in this example), and the recently determined TIL information (2.2 U insulin load in this example). In another example, as shown in FIG. 2, the display 222 of the user interface 220 provides a default screen that provides the time (10:30 AM in this example), the blood glucose level (118 mg/dl in this example), the indication of whether the user's blood glucose level is rising or falling (the upward arrow indicates a rising glucose level in this example), and the recently calculated TIL information (a 10% load in this example, which represents a normalized value of the TIL calculation as described below in connection with FIG. 13).

In operation 440, the process 400 can return to initiate a new TIL calculation after a period of time. For example, the operation 440 can cause the controller device 200 to calculate the TIL for time t_n+1by returning to operation 405. As previously described, the controller device 200 can initiate the subsequent TIL calculation for the subsequent time t_n+1based on a request from the user or based on a program that causes calculation of the TIL information on a periodic basis (e.g., every 1 minute, every 2 minutes, every 5 minutes, every 10 minutes, every 30 minutes, or the like). The subsequent TIL value for time t_n+1can be stored in the memory of the controller device 200 (e.g., in the previously described database) and can be displayed on the user interface 220 of the controller device 200.

Referring now to FIG. 12, in some embodiments, the controller device 200 can calculate the TIL information using, at least in part, time-based models derived from pharmacodynamic data. As previously described, the TIL value of a user can include a bolus insulin load component and a basal insulin load component, each of which may be determined using a time-decay model generated from pharmacodynamic data associated with the insulin stored in the cartridge 120. As shown by way of example in FIG. 12, the controller device 200 can utilize a time-decay curve (represented by curve 450), which is generated from pharmacodynamic data, to estimate the percentage of insulin remaining in a user's body after a particular period of time.

Referring now to FIG. 13, graph 500 is an exemplary depiction of how a constant basal delivery can affect a user's TIL information. In this example, the basal insulin deliveries are represented as a series of basal infusion points 506 (e.g., dosages of 0.25 U every fifteen minutes to provide a basal rate of 1.0 U per hour). It should be understood from the description herein that, while the basal rate is sometimes described as a generally continuous administration, it can be implemented as a series of small injections given at regular intervals. Because the basal rate is constant over a period of seven hours with no bolus dosages, the insulin delivery pattern 505 is represented as a horizontal, straight line that depicts a constant basal rate of 1.0 units/hour. For the purposes of this example, it is presumed that there were no basal or bolus insulin deliveries prior to time=0 (hours), there were no previously consumed carbohydrates acting on the user's total insulin load, and that the user's TIL (represented by TIL curve 510) was also 0.0 prior to time=0. This may occur, for example, after the user wakes in the morning and then activates the pump assembly 60 to deliver the basal insulin. As such, the user's TIL value has only a single component (basal insulin load) and is equal to zero before time=0. The other components of the TIL calculation, such as the bolus insulin load and the previous food component, are zero in this example. At time=0 the first basal infusion (represented by point 507) of 0.25 units is made. Since substantially none of the insulin delivered in the first infusion (point 507) has acted on the user at time=0, the entire contents of the infusion (0.25 units) are now part of the TIL, which is reflected in the TIL curve 510. With the subsequent boluses 508 and 509, the TIL increases, while some small portion of the previously dispensed insulin acts in the blood stream. This is estimated from a time-decay curve (refer, for example, to FIG. 12), which is generated from pharmacodynamic data. As time increases, however, the amount of insulin leaving the insulin load and entering the blood stream increases until point 512 where the amount of insulin leaving the insulin load to act in the blood stream is substantially equal to the amount of insulin entering the insulin load due to the constant basal infusion. If the basal rate remains constant, than the TIL will continue to remain at the equilibrium value shown on the graph 500. In this example, the TIL reaches equilibrium at a value of about 2.25 U (as shown on the left-side axis in graph 500). FIG. 13 depicts a dashed line 514 that represents a TIL value of about 2.25 U. FIG. 13 depicts a dashed line 515 that represents a TIL value of about 2.5 U.

Referring now to FIG. 15, as previously described, the TIL information can be determined in a manner that accounts for both the bolus deliveries and the basal deliveries (not merely previous bolus deliveries). As such, the TIL values may accurately reflect basal rate changes and the impact of stopping insulin delivery (e.g., during periods in which insulin delivery is stopped or basal delivery is altered, during activities such as swimming or another exercise, etc.). The insulin delivery pattern in FIG. 15 is similar to the previously described scenario shown in FIG. 14, except that the basal delivery is stopped between time=5 hours and time=7 hours (refer to the basal delivery curve 710 in graph 700). For example, the graph 700 includes a region 740, in which the basal infusion rate remains constant and no boluses are infused, so the TIL curve 720 approaches a constant value while the TIL % curve 730 remains at 0% (similar to the previously described scenario shown in FIG. 14). At about time=5 hours, basal delivery is suspended for a period of approximately two hours (refer to region 750). As a result, the TIL curve 720 decays or otherwise reduces in that period of time because the previously dispensed insulin transitions to act in the user's blood stream (e.g., to lower or otherwise affect the user's blood glucose level) and no further insulin is being dispensed during that time period. Also, in the example depicted in FIG. 15, the TIL % curve 730 transitions into negative values (e.g., −25%, −50%, etc.) because the insulin dosages were ceased between time=5 hours and time=7 hours. During such periods of ceased insulin delivery, the actual TIL value may become less than theoretical TIL_basal(e.g., the TIL that would have been generated based on the user's basal insulin dosages), which causes the TIL % values to transition into negative values. In one example, the user may readily recognize that his or her insulin load (e.g., TIL %=−25%) is approximately ¼th less than what it normally would have been if he or she had maintained the scheduled basal insulin delivery rate. Accordingly, the TIL values and the TIL % values can accurately reflect basal rate changes and the impact of stopping insulin delivery.

As shown in FIG. 15, the basal insulin rate restarts at about time=7 hours, which causes the TIL value to increase and the TIL % value to return toward 0%. In this example, a bolus delivery 714 of about 5 units is delivered to the user at about time=8 hours, thereby raising the user's TIL value about 5 units to slightly higher than 6 units. Such a bolus delivery 714 also causes the TIL % value to increase to slightly less than 200% in this example. This normalized value indicates to the user that the TIL is slightly less than two times what it would ordinarily be if the user had maintained just the constant basal rate (from region 740) without any bolus delivery 714. In region 760, the user's TIL value and the TIL % value decays or otherwise decreases as the previously dispensed insulin transitions to act in the user's blood stream (e.g., to lower or otherwise affect the user's blood glucose level). With subsequent bolus deliveries 716 and 718 at about time=10 and time=12 hours respectively, the user's TIL value and the TIL % value increases with each bolus, and thereafter decays. FIG. 15 depicts line 710, which represents basal infusions. FIG. 15 depicts basal infusions 712.

Referring now to FIG. 16A, the TIL value may return to a constant value (and the TIL % value may return to 0%) after an extended period of time with no bolus activity. For example, the graph 800 in FIG. 16A is similar to the previously described graph in FIG. 15, except that it shows the insulin delivery pattern over a greater duration of time. In some embodiments, a user may continue to receive insulin deliveries from the pump assembly 60 during his or her period of sleep. The user can receive only his or her ordinary basal dosages during this period of sleep so as to maintain his or her blood glucose level within a safe range. In the example depicted in FIG. 16A, the user receives a bolus delivery 819 before a dinner meal at about time=18 hours. Thereafter, no further bolus dosages are provided for the remainder of the day, and the user receives only the ordinary basal rate delivery (refer to region 870 in FIG. 16A). During this extended period of receiving only the basal deliveries as shown in region 870, the TIL values (refer to TIL curve 820) decay or otherwise decrease from a value greater than 10 units of insulin to a constant value of slightly greater than 2 units. Also, during this extended period in region 870, the TIL % values (refer to TIL % curve 830) decay or otherwise decrease from a normalized value of almost 400% to the constant value of 0%. Accordingly, over a period of a day or more, the TIL value and the TIL % value can “reset” or otherwise return to a constant value during periods of sleep (when the user receives nighttime basal dosages) or during other extended periods during which no bolus activity occurs. FIG. 16A depicts line 810 that represents basal infusions. FIG. 16A depicts basal infusions 812. FIG. 16A depicts regions 850 and 860. FIG. 16A depicts bolus delivery 814. FIG. 16A depicts dashed line 820, which represents a TIL % curve. FIG. 16A depicts solid line 830, which represents a TIL curve.

In the previous examples, described in connection with FIGS. 14-16A, the controller device 200 calculated the TIL at any given time by summing the insulin load due to basal delivery and the insulin load due to one or more bolus deliveries (if any). These examples depict embodiments of the controller device 200 that provide the advantage of using more accurate insulin action curves to estimate the amount of insulin that has been delivered to a user (but not yet acted in that user's blood stream), and the advantage of including a basal insulin load component to the TIL calculation (thus incorporating all delivered insulin in the TIL calculation). As described previously, a calculated TIL value can be used to, for example, predict future blood glucose levels and/or can be used in the calculation of suggested bolus amounts. As such, the controller device 200 can employ the TIL information to provide accurate information to the user and to avoid “bolus stacking” and unsafe swings in blood glucose level.

In much the same way that insulin does not immediately enter the blood stream and act upon a user after subcutaneous delivery, ingested carbohydrates can also take time to fully act upon the user's blood glucose level. In some embodiments, the controller device 200 can also include a component in the TIL calculation that takes into account food which has been previously consumed but not yet acted in the user.

Referring now to FIG. 16B, as previously described, the TIL information can account for the user's previously consumed food in addition to the bolus deliveries and the basal deliveries. In these circumstances, the TIL values may accurately reflect both the previously dispensed insulin that has not yet acted and the previously consumed food that has not yet been metabolized. The insulin delivery pattern in FIG. 16B is similar to the previously described scenario shown in FIG. 16A, except that the user in FIG. 16B skips a bolus delivery at time=12 hours (note that FIG. 16A shows a bolus delivery 816 at time=12 hours). Also, in the example depicted in FIG. 16, the TIL calculation process also accounts for previously consumed food (e.g., the previous food component). For example, the graph 900 in FIG. 16B includes a basal delivery curve 910 made up of individual basal infusions 912, a TIL curve 920, and a TIL % curve 930. At about time=12 hours, the user enters meal data into the controller device 200, but no bolus delivery is dispensed (e.g., due to user error or another reason), leading to an immediate drop in the TIL curve 920 and the TIL % curve 930. This substantial decrease in the TIL value and the TIL % value is due to the fact that the process for calculating the TIL information accounts for the user's previously consumed food intake (in addition to the bolus deliveries and the basal deliveries). Thus, the controller device 200 receives information at time=12 hours that the user has consumed food but no bolus delivery was provided (e.g., a “missed bolus” situation). As such, the previous food component of the TIL calculation becomes much more significant than the bolus load component and the basal load component (thereby driving the TIL value and the TIL % value into the negative value range). In some embodiments, this drop of the TIL curve 920 into the negative region could result in the controller device 200 alerting the user to a potentially unsafe condition (e.g., a significant rise in blood glucose level) long before the user's blood glucose level begins to rise outside of a targeted range. Such a safety feature can provide enhanced protection for the user, who would have the opportunity to select a correction bolus before the blood glucose level increased to unsafe conditions.

Still referring to FIG. 16B, at about time=18 hours, a bolus delivery 915 is provided to the user, but no meal data is entered into the controller device 200. Unlike the previous situation at time=12 hours in which the user missed a bolus dosage, this may represent a “missed meal” situation at time=18 hours. This situation may occur, for example, where the user intends to eat a meal and schedules a bolus dosage, but then forgets or fails to consume the proposed meal. Such conditions can lead to a sharp increase in the TIL curve 920 and the TIL % curve 930. As such, the bolus load component of the TIL calculation becomes much more significant than the previous food component (thereby driving the TIL value and the TIL % value upward into the higher value range). In some embodiments, this sharp increase of the TIL curve 920 could result in the controller device 200 alerting the user to a potentially unsafe condition (e.g., a significant drop in blood glucose level) long before the user's blood glucose level begins to fall outside of a targeted range. Such a safety feature can provide enhanced protection for the user, who would have the opportunity to consume food items and enter the food data in the controller device 300 before the glucose level decreased to unsafe conditions. If the user did consume food at about time=18 hours but merely forgot to enter the information into the controller device 200, the user would have the opportunity to enter the meal information, thus causing the next TIL calculation to be corrected. For example, in response to the alert from the controller device 200, the controller device may prompt the user to enter the previous food information (if he or she forgot to enter the meal information) or to start the consumption of food items.

Similar to embodiments previously described in connection with FIG. 16A, the TIL value may return to a constant value (and the TIL % value may return to 0%) after an extended period of time with no bolus activity and no food consumption activity. In this example shown in FIG. 16B, during the period between time=18 hours and time=24 hours, the user may cease bolus activity and food consumption (e.g., as he or she prepares for sleep and begins to sleep overnight). During this extended period of receiving only the basal deliveries as shown in region 970, the TIL values (refer to TIL curve 920) decay or otherwise decrease to a constant value of slightly greater than 2 units. Also, during this extended period in region 970, the TIL % value (refer to TIL % curve 930) decay or otherwise decrease to a constant value of 0%. FIG. 16B depicts bolus deliveries 914 and 919. FIG. 16B depicts region 960.

Referring now to FIG. 17, some embodiments of a process 1000 for the calculation of a suggested bolus amount can include a number of operations performed by the controller device 200 in response to user input. For example, when the user intends to consume a meal, the user can select a bolus insulin delivery to offset the blood glucose effects caused by the carbohydrates consumed with the meal. In another example, a user's blood glucose may be significantly higher than a targeted level, so the controller device 200 can suggest a correction bolus amount that will lower the blood glucose level into an acceptable range. As described in connection with FIG. 17, the controller device 200 can also take into account the user's TIL information when calculating the suggested bolus amount to the user.

In operation 1005, the controller device 200 can receive a request to suggest a bolus dosage. An exemplary request can come from the user that interacts with the user interface 220 of the controller device 200. For example, the user may request a suggested insulin bolus amount during preparation for a proposed meal. As described below, the suggested bolus value can be calculated from at least three components: a food bolus value (to offset the blood glucose effects caused by the proposed meal), a correction bolus value (to reduce the current blood glucose level into an acceptable range), and the TIL value (as previously described in connection with FIG. 11).

In operation 1010, the controller device 200 can receive input from the user indicating the amount of food to consumed. For example, the user can enter the amount and type of food that is to be consumed and the controller device 200 can determine the amount of carbohydrates contained in the food to be consumed. In another example, the user can determine the amount of carbohydrates in a proposed meal and enter this value into the controller device 200 (e.g., grams of carbohydrates or the like). In operation 1015, the controller device 200 can calculate the amount of bolus insulin to offset the proposed food intake as entered in operation 1010 (e.g., the food bolus value). For example, the number of carbohydrates determined in operation 1010 can be divided by a carbohydrate ratio (e.g., 15 grams of carbohydrates per 1 unit of insulin) to determine the dosage of bolus insulin to offset the potential blood glucose effects caused by the proposed meal.

In operation 1020, the controller device 200 can receive information indicative of the user's current blood glucose level. For example, the controller device 200 can receive information indicative of the user's blood glucose level from the glucose monitoring device 50. In another example, the user can utilize a separate blood glucose meter (e.g., a blood strip reader) and enter the results into the controller device 200. Alternatively, the glucose meter device can wirelessly communicate the blood glucose information to the controller device 200 (via communication with wireless communication device 247).

In operation 1025, the controller device 200 can calculate the amount of insulin (if any) to correct the current blood glucose level based on the information obtained during operation 1020. For example, the controller device 200 can subtract the user's target blood glucose level from the current level obtained during operation 1020, and then multiply this difference by an insulin sensitivity factor. Such a calculation can provide a correction bolus value that is indicative of the amount of insulin that is appropriate to reduce the current blood glucose level into an acceptable range. A positive correction bolus value indicates that the current blood glucose level is high, thereby requiring additional insulin to correct. Conversely, a negative correction bolus value indicates that the current blood glucose value is low, which will cause the suggested total bolus to be decreased.

In operation 1030, the controller device 200 can retrieve a TIL value stored in memory (previously described in connection with FIG. 11). To reduce the likelihood of undesirable bolus stacking, the TIL information can be determined by the controller device 200 on a periodic basis so that the user can be aware of the previously dispensed insulin which has not yet acted in the user's body. This TIL information can be used in a bolus suggestion feature of the controller device 200 so that the suggested bolus amount accounts for the previously dispensed insulin (both basal and bolus dosages) which has not yet acted in the user's body and (optionally) the previous food intake of the user. The TIL value can be stored in a memory device 248 (FIG. 9) of the controller device 200. As an alternative to retrieving the TIL value from the memory device, the controller device 200 can calculate a current TIL value using a process, for example, as previously described in connection with FIG. 11.

In operation 1035, the controller device 200 can calculate a suggested bolus dosage based, at least in part, on the information provided by the user. In one example, the suggest bolus dosage can be determined according to the following equation:

Suggested Bolus Dosage=Food Bolus+Correction Bolus−TIL Value

As such, the controller device 200 can provide a bolus suggestion feature that accounts for the user's TIL when suggesting a new bolus of insulin prior to a meal or other food intake. By so including the TIL information in the suggested bolus calculation, which accounts for the amount of previous basal and bolus insulin that has not yet acted in the user's body, the controller device 200 can reduce the likelihood of the user performing an unsafe level of bolus stacking. Moreover, in some embodiments, the TIL information can reflect the user's previously consumed food in addition to the bolus deliveries and the basal deliveries. Accordingly, the suggested bolus calculation, which includes the TIL information, can account for both the previously dispensed insulin that has not yet acted and the previously consumed food that has not yet been metabolized.

In operation 1040, the controller device 200 can inform the user (e.g., through controller device 200, through an audio output, or through another component of the user interface) of the bolus suggestion. In one example, the display device 222 can communicate the suggested bolus amount to the user so that the user can manually input the suggested bolus value into a bolus scheduling module of controller device 200 (e.g., a separate menu option). Alternatively, as indicated in operation 1045, the controller device 200 can prompt the user to begin bolus delivery according to the suggested bolus dosage. For example, the controller device 200 can display the suggested bolus value along with a prompt that asks the user to confirm the start of the suggested bolus dosage. If the user responds in the affirmative, the controller device 200 can automatically begin the infusion. If the user responds in the negative, the user can have the opportunity manually input the suggested bolus value into a bolus scheduling module of controller device 200 (e.g., a separate menu option).

Referring now to FIGS. 18 and 19, in some circumstances, the TIL information that is collected over a period of time can be accessed by the user or a health care provider for purposes of analysis and program adjustments. As previously described, the TIL information at time t_nand the time data t_ncan be stored in the memory of the controller device 200. The memory of the controller device 200 may also store the detected blood glucose level at time t_n, which may be generated from the sensor signal received from the monitoring device 50 (FIG. 1). As such, the data stored in the controller device 200 can provide a historical record of the TIL information, the time information, and (optionally) the detected blood glucose information that is accessible by the controller device 200 or by an external computer system (e.g., a desktop computer, a laptop computer, a PDA, or the like).

For example, as shown in FIG. 18, the controller device 200 can store the TIL information and other data related to a user's blood glucose level in the memory device 248 (FIG. 9) and subsequently transfer this data to an external computer system 80 of the user or the user's health care provider. In some embodiments, the external computer system 80 can display a plot of the historical data and (optionally) execute a software program to analyze the historical data for the purposes of helping the user to better manage his or her diabetes treatment. This analysis can be used, for example, to educate the user about the benefits of entering meal information in an accurate and timely manner, to properly adjust the user's basal rate schedule, to modify user-specific parameters programmed in the controller device 200 (e.g., the carbohydrate ratio, insulin sensitivity, and the like), and to perform other management tasks.

In this illustrative example depicted in FIG. 18, the controller device 200 may communicate data to an external computer system 80 via a data connection 85. As previously described, the controller device 200 may include a cable connector (e.g., a USB connection port, another data cable port, or a data cable connection via the electrical connector 218) that is accessible on an external portion of the controller housing 210. As such, a data cable may be connected to the control circuitry 240 to export the data to the external computer system 80. Alternatively, the data connection 85 can be a wireless connection via the controller's wireless communication device 247. In such circumstances, the wireless communication device 247 can be configured to wirelessly communicate with the monitoring device 50 (FIG. 1) and with the external computer system 80 (FIG. 18). When the controller device 200 is connected to the computer system 80 via the data connection 85, the controller device 200 can execute a data exporting module in which the TIL information, the time information, the detected blood glucose information, and other treatment information is exported in a suitable format to the external computer system 80. In some circumstances, the controller device 200 may be detached from the pump device during the process of exporting data, so the controller device 200 can suspend dispensation operations (e.g., suspends basal infusion, bolus infusion, accessibility to certain menus via the user interface 220, and the like). While controller device executes the data exporting module, the controller device 200 may indicate on the display device 222 that the controller device 200 is in this mode by displaying a message such as “Exporting Data . . . ” or the like. Still referring to FIG. 18, after the data has been transferred to the computer system 80, the computer system 80 can display the TIL information and other treatment data is a usable format. For example, the display device of the computer system 80 can provide a time-based plot 82 that indicates the user's insulin delivery pattern 84 and the user's TIL information 86 with respect to time. The TIL information in the plot 82 can be display as the actual TIL value (in units of insulin), the TIL % value (normalized to be a percentage), or both. The computer system 80 may provide a time-based plot that indicates the user's detected blood glucose levels with respect to time. Optionally, this blood glucose information can be display on the same plot 82 as the TIL information 86. Thus, the external computer system 80 can display the plot 82 of the user's historical treatment data and may optionally execute a software program to analyze the historical treatment data for the purposes of helping the user to better manage his or her diabetes treatment. By presenting the TIL information and other treatment data to the user in an understandable, graphical format (such as the time-based plot 82), the health care provider is readily equipped to educate the user about the benefits of entering meal information in an accurate and timely manner, to properly adjust the user's basal rate schedule, to modify user-specific parameters programmed in the controller device 200 (e.g., the carbohydrate ratio, insulin sensitivity, and the like), and to perform other management tasks.

In another illustrative example depicted in FIG. 19, some embodiments of the controller device 200 can be configured to display the TIL information and other treatment data is a graphical format data on the local display device 222. For example, as shown in FIG. 19, the controller device 200 can access the historical treatment data stored in the memory device 248 so as to generate a graphical bar graph representation 226 of the TIL information over a period of time. In this embodiment, the TIL information is displayed on the display device in the form of a bar graph 226 that indicates the user's TIL information over a period of hours. The display 22 can be configured to display a y-axis that is representative of the scale for the TIL value of the TIL % value. Also, the display device 222 can shows a set of time increments along an x-axis of the bar graph 226. As such, the controller device 200 can provide prompt access to the TIL information by a user or health care provider, and can readily present such information in an understandable, graphical format (such as the time-based plot bar graph 226). In doing so, the user can assess his or her insulin treatment performance over a recent period of time and make proper adjustments to his or her basal rate, bolus dosages, eating schedule, or the like. In the event that the user seeks to review the TIL information over a longer period of time, the controller device 200 can display the TIL values for this extended period (e.g., a 24-hour period) on the display device 222 by averaging the TIL values during each one hour period into a single value. In such circumstances, the hour-averaged values (e.g., 24 averaged values for a 24 hour period) can then be displayed in a graphical format, such as bar graph, that indicates the trends of the user's TIL information.

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

Claims

1. A system, comprising: a pump housing that receives insulin for dispensation to a user, the pump housing at least partially containing a pump drive system to dispense insulin through a flow path to the user;a controller that instructs the pump drive system to dispense the insulin from the pump housing, wherein the controller is configured to receive glucose information being indicative of a glucose level of the user; andan external computer including a display in wireless communication with the controller,wherein the system determines a total insulin load according to a function that accounts for a bolus insulin load and a basal insulin load, and calculates future glucose level of the user, andwherein the total insulin load is a normalized total insulin load (TIL) percentage value and the system utilizes the normalized TIL percentage value to calculate the future glucose level of the user.
2. The system of claim 1, wherein the function further accounts for a previous food component based upon previous food intake that has not yet metabolized in the user.
3. The system of claim 1, wherein the system displays to a user a glucose value indicative of the glucose level of the user and the total insulin load.
4. The system of claim 3, wherein the glucose value and the total insulin load are contemporaneously displayed to the user.
5. The system of claim 1, wherein the total insulin load is determined by the controller.
6. The system of claim 1, further comprising a computer-readable memory device coupled to the controller that stores one or more calculated values for the total insulin load and one or more corresponding time values.
7. The system of claim 1, wherein the controller comprises a controller housing that removably attaches to the pump housing, the controller being electrically connected to the pump drive system when the controller housing is removably attached to the pump housing.
8. The system of claim 1, wherein the controller is a reusable device, and wherein the pump housing and pump drive system are components of a disposable and nonreusable pump device having one or more structures that hinder reuse of the pump device after a supply of the insulin is exhausted.
9. The system of claim 1, wherein the pump housing receives a prefilled cartridge through an opening of the pump housing that is coverable with a cap device.
10. The system of claim 9, wherein the flow path of the insulin comprises an infusion set tube that extends from the cap device to the user.
11. The system of claim 1, wherein the total insulin load is determined based on a user input request.
12. The system of claim 1, wherein the total insulin load is automatically determined at predetermined intervals.
13. The system of claim 1, wherein the normalized total insulin load (TIL) percentage value is determined according to the function: total insulin load percentage=[(Actual TIL)−(theoretical TILbasal)]/(theoretical TILbasal)×100where theoretical TILbasal represents the TIL that would have been generated based only on the user's basal insulin dosages.
14. The system of claim 1, wherein the system alerts the user when the total insulin load is a negative value.
15. The system of claim 1, wherein the system alerts the user when the total insulin load increases at a rate above a predetermined rate indicative of a potentially unsafe condition.
16. The system of claim 1, wherein the total insulin load is a numerical value that is displayed to the user.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/948,356, filed Apr. 9, 2018, now U.S. Pat. No. 10,737,015, issued on Aug. 11, 2020, which is a continuation of U.S. application Ser. No. 14/797,400, filed Jul. 13, 2015, now U.S. Pat. No. 9,968,729, issued on May 15, 2018, which is a continuation of U.S. application Ser. No. 13/524,200 filed on Jun. 15, 2012, now U.S. Pat. No. 9,078,963, issued on Jul. 14, 2015, which is a continuation of U.S. application Ser. No. 13/071,061 filed on Mar. 24, 2011, now U.S. Pat. No. 8,221,385, issued on Jul. 17, 2012, which is a divisional of U.S. application Ser. No. 12/195,034 filed on Aug. 20, 2008, now U.S. Pat. No. 7,959,598, issued on Jun. 14, 2011, the entire contents of these previous applications are expressly incorporated herein by reference.

US Referenced Citations (1780)

Number	Name	Date	Kind
303013	Horton	Aug 1884	A
445545	Crane	Feb 1891	A
588583	Lade	Aug 1897	A
1441508	Marius et al.	Jan 1923	A
2283925	Harvey	May 1942	A
2605765	Kollsman	Aug 1952	A
2797149	Skeggs	Jun 1957	A
2886529	Guillaud	May 1959	A
3413573	Nathanson et al.	Nov 1968	A
3574114	Monforte	Apr 1971	A
3614554	Shield et al.	Oct 1971	A
3631847	Hobbs	Jan 1972	A
3634039	Brondy	Jan 1972	A
3688764	Reed	Sep 1972	A
3812843	Wootten et al.	May 1974	A
3841328	Jensen	Oct 1974	A
3885662	Schaefer	May 1975	A
3886938	Szabo et al.	Jun 1975	A
3963380	Thomas et al.	Jun 1976	A
3983077	Fuller et al.	Sep 1976	A
4055175	Clemens et al.	Oct 1977	A
4077405	Haerten et al.	Mar 1978	A
4108177	Pistor	Aug 1978	A
4146029	Ellinwood, Jr.	Mar 1979	A
4151845	Clemens	May 1979	A
4231368	Becker	Nov 1980	A
4235234	Martin et al.	Nov 1980	A
4245634	Albisser et al.	Jan 1981	A
4265241	Portner et al.	May 1981	A
4268150	Chen	May 1981	A
4295176	Wittwer	Oct 1981	A
4300554	Hessberg et al.	Nov 1981	A
4313439	Babb et al.	Feb 1982	A
4368980	Aldred et al.	Jan 1983	A
4373527	Fischell	Feb 1983	A
4398908	Siposs	Aug 1983	A
4400683	Eda et al.	Aug 1983	A
4403984	Ash et al.	Sep 1983	A
4424720	Bucchianeri	Jan 1984	A
4435173	Siposs et al.	Mar 1984	A
4443218	DeCant et al.	Apr 1984	A
4464170	Clemens et al.	Aug 1984	A
4469481	Kobayashi	Sep 1984	A
4475901	Kraegen et al.	Oct 1984	A
4493704	Beard et al.	Jan 1985	A
4498843	Schneider et al.	Feb 1985	A
4507115	Kambara et al.	Mar 1985	A
4523170	Huth, III	Jun 1985	A
4526568	Clemens et al.	Jul 1985	A
4526569	Bernardi	Jul 1985	A
4529401	Leslie et al.	Jul 1985	A
4551134	Slavik et al.	Nov 1985	A
4552561	Eckenhoff et al.	Nov 1985	A
4559033	Stephen et al.	Dec 1985	A
4559037	Franetzki et al.	Dec 1985	A
4562751	Nason et al.	Jan 1986	A
4564054	Gustavsson	Jan 1986	A
4573968	Parker	Mar 1986	A
4585439	Michel	Apr 1986	A
4601707	Albisser et al.	Jul 1986	A
4624661	Arimond	Nov 1986	A
4633878	Bombardieri	Jan 1987	A
4634427	Hannula et al.	Jan 1987	A
4646038	Wanat	Feb 1987	A
4652260	Fenton et al.	Mar 1987	A
4657529	Prince et al.	Apr 1987	A
4668220	Hawrylenko	May 1987	A
4678408	Nason et al.	Jul 1987	A
4681569	Coble et al.	Jul 1987	A
4684368	Kenyon	Aug 1987	A
4685903	Cable et al.	Aug 1987	A
4731726	Allen, III	Mar 1988	A
4734092	Millerd	Mar 1988	A
4743243	Vaillancourt	May 1988	A
4749109	Kamen	Jun 1988	A
4755169	Sarnoff et al.	Jul 1988	A
4755173	Konopka et al.	Jul 1988	A
4759120	Bernstein	Jul 1988	A
4768506	Parker et al.	Sep 1988	A
4781688	Thoma et al.	Nov 1988	A
4781693	Martinez et al.	Nov 1988	A
4808161	Kamen	Feb 1989	A
4838857	Strowe et al.	Jun 1989	A
4850817	Nason et al.	Jul 1989	A
4854170	Brimhall et al.	Aug 1989	A
4859492	Rogers et al.	Aug 1989	A
4880770	Mir et al.	Nov 1989	A
4886499	Cirelli et al.	Dec 1989	A
4898578	Rubalcaba, Jr.	Feb 1990	A
4898579	Groshong et al.	Feb 1990	A
4900292	Berry et al.	Feb 1990	A
4902278	Maget et al.	Feb 1990	A
4919596	Slate et al.	Apr 1990	A
4925444	Orkin et al.	May 1990	A
4940527	Kazlauskas et al.	Jul 1990	A
4944659	Labbe et al.	Jul 1990	A
4967201	Rich, III	Oct 1990	A
4969874	Michel et al.	Nov 1990	A
4975581	Robinson et al.	Dec 1990	A
4976720	Machold et al.	Dec 1990	A
4981140	Wyatt	Jan 1991	A
4994047	Walker et al.	Feb 1991	A
5007286	Malcolm et al.	Apr 1991	A
5007458	Marcus et al.	Apr 1991	A
5029591	Teves	Jul 1991	A
5045064	Idriss	Sep 1991	A
5061424	Karimi et al.	Oct 1991	A
5062841	Siegel	Nov 1991	A
5084749	Losee et al.	Jan 1992	A
5088981	Howson et al.	Feb 1992	A
5088990	Hivale et al.	Feb 1992	A
5097834	Skrabal	Mar 1992	A
5102406	Arnold	Apr 1992	A
5109850	Blanco et al.	May 1992	A
5125415	Bell	Jun 1992	A
5130675	Sugawara	Jul 1992	A
5134079	Cusack et al.	Jul 1992	A
5139999	Gordon et al.	Aug 1992	A
5153827	Coutre et al.	Oct 1992	A
5154973	Imagawa et al.	Oct 1992	A
5165406	Wong	Nov 1992	A
5176632	Bernardi	Jan 1993	A
5176662	Bartholomew et al.	Jan 1993	A
5178609	Ishikawa	Jan 1993	A
5189609	Tivig et al.	Feb 1993	A
5190522	Wojcicki et al.	Mar 1993	A
5198824	Poradish	Mar 1993	A
5205819	Ross et al.	Apr 1993	A
5207642	Orkin et al.	May 1993	A
5209230	Swedlow et al.	May 1993	A
5213483	Flaherty et al.	May 1993	A
5217754	Santiago-Aviles et al.	Jun 1993	A
5219377	Poradish	Jun 1993	A
5225763	Krohn et al.	Jul 1993	A
5232439	Campbell et al.	Aug 1993	A
5237993	Skrabal	Aug 1993	A
5244463	Cordner et al.	Sep 1993	A
5250027	Lewis et al.	Oct 1993	A
5254096	Rondelet et al.	Oct 1993	A
5257980	Van et al.	Nov 1993	A
5261882	Sealfon	Nov 1993	A
5263198	Geddes et al.	Nov 1993	A
5272485	Mason et al.	Dec 1993	A
5273517	Barone et al.	Dec 1993	A
5281202	Weber et al.	Jan 1994	A
5281808	Kunkel	Jan 1994	A
5299571	Mastrototaro	Apr 1994	A
5308982	Ivaldi et al.	May 1994	A
5314412	Rex	May 1994	A
5335994	Weynant Nee Girones	Aug 1994	A
5338157	Blomquist	Aug 1994	A
5342180	Daoud	Aug 1994	A
5342298	Michaels et al.	Aug 1994	A
5346476	Elson	Sep 1994	A
5349575	Park	Sep 1994	A
5364342	Beuchat et al.	Nov 1994	A
5377674	Kuestner	Jan 1995	A
5380665	Cusack et al.	Jan 1995	A
5385539	Maynard	Jan 1995	A
5389078	Zalesky et al.	Feb 1995	A
5395340	Lee	Mar 1995	A
5403797	Ohtani et al.	Apr 1995	A
5411487	Castagna	May 1995	A
5411889	Hoots et al.	May 1995	A
5421812	Langley et al.	Jun 1995	A
5427988	Sengupta et al.	Jun 1995	A
5433710	VanAntwerp et al.	Jul 1995	A
5456945	McMillan et al.	Oct 1995	A
5468727	Phillips et al.	Nov 1995	A
5478610	Desu et al.	Dec 1995	A
5505709	Funderburk et al.	Apr 1996	A
5505828	Wong et al.	Apr 1996	A
5507288	Boecker et al.	Apr 1996	A
5513382	Agahi-Kesheh et al.	Apr 1996	A
5527288	Gross et al.	Jun 1996	A
5533389	Kamen et al.	Jul 1996	A
5535445	Gunton	Jul 1996	A
5540772	McMillan et al.	Jul 1996	A
5543773	Evans et al.	Aug 1996	A
5545143	Fischell et al.	Aug 1996	A
5551850	Williamson et al.	Sep 1996	A
5554123	Herskowitz	Sep 1996	A
5558640	Pfeiler et al.	Sep 1996	A
5569186	Lord et al.	Oct 1996	A
5582593	Hultman	Dec 1996	A
5584053	Kommrusch et al.	Dec 1996	A
5584813	Livingston et al.	Dec 1996	A
5590387	Schmidt et al.	Dec 1996	A
5609572	Lang	Mar 1997	A
5614252	McMillan et al.	Mar 1997	A
5625365	Tom et al.	Apr 1997	A
5626566	Petersen et al.	May 1997	A
5635433	Sengupta	Jun 1997	A
5637095	Nason et al.	Jun 1997	A
5656032	Kriesel et al.	Aug 1997	A
5665065	Colman et al.	Sep 1997	A
5665070	McPhee	Sep 1997	A
5672167	Athayde et al.	Sep 1997	A
5678539	Schubert et al.	Oct 1997	A
5685844	Marttila	Nov 1997	A
5685859	Kornerup	Nov 1997	A
5693018	Kriesel et al.	Dec 1997	A
5697899	Hillman et al.	Dec 1997	A
5700695	Yassinzadeh et al.	Dec 1997	A
5703364	Rosenthal	Dec 1997	A
5707459	Itoyama et al.	Jan 1998	A
5707715	Derochemont et al.	Jan 1998	A
5713875	Tanner, II	Feb 1998	A
5714123	Sohrab	Feb 1998	A
5716343	Kriesel et al.	Feb 1998	A
5718562	Lawless et al.	Feb 1998	A
5722397	Eppstein	Mar 1998	A
5741216	Hemmingsen et al.	Apr 1998	A
5741228	Lambrecht et al.	Apr 1998	A
5746217	Erickson et al.	May 1998	A
5747350	Sattler	May 1998	A
5747870	Pedder	May 1998	A
5748827	Holl et al.	May 1998	A
5755682	Knudson et al.	May 1998	A
5758643	Wong et al.	Jun 1998	A
5759923	McMillan et al.	Jun 1998	A
5764189	Lohninger	Jun 1998	A
5766155	Hyman et al.	Jun 1998	A
5771567	Pierce et al.	Jun 1998	A
5772635	Dastur et al.	Jun 1998	A
5776103	Kriesel et al.	Jul 1998	A
5779676	Kriesel et al.	Jul 1998	A
5785688	Joshi et al.	Jul 1998	A
5797881	Gadot	Aug 1998	A
5800397	Wilson et al.	Sep 1998	A
5800405	McPhee	Sep 1998	A
5800420	Gross et al.	Sep 1998	A
5801057	Smart et al.	Sep 1998	A
5804048	Wong et al.	Sep 1998	A
5807075	Jacobsen et al.	Sep 1998	A
5816306	Giacomel	Oct 1998	A
5817007	Fodgaard et al.	Oct 1998	A
5820622	Gross et al.	Oct 1998	A
5822715	Worthington	Oct 1998	A
5823951	Messerschmidt	Oct 1998	A
5839467	Saaski et al.	Nov 1998	A
5840020	Heinonen et al.	Nov 1998	A
D403313	Peppel	Dec 1998	S
5848991	Gross et al.	Dec 1998	A
5851197	Marano et al.	Dec 1998	A
5852803	Ashby et al.	Dec 1998	A
5854608	Leisten	Dec 1998	A
5858001	Tsals et al.	Jan 1999	A
5858005	Kriesel	Jan 1999	A
5858239	Kenley et al.	Jan 1999	A
5859621	Leisten	Jan 1999	A
5865806	Howell	Feb 1999	A
5871470	McWha	Feb 1999	A
5873731	Prendergast	Feb 1999	A
5879310	Sopp et al.	Mar 1999	A
5889459	Hattori et al.	Mar 1999	A
5891097	Saito et al.	Apr 1999	A
5892489	Kanba et al.	Apr 1999	A
5893838	Daoud et al.	Apr 1999	A
5897530	Jackson	Apr 1999	A
5902253	Pfeiffer et al.	May 1999	A
5903421	Furutani et al.	May 1999	A
5906597	McPhee	May 1999	A
5911716	Rake et al.	Jun 1999	A
5914941	Janky	Jun 1999	A
5919167	Mulhauser et al.	Jul 1999	A
5925018	Ungerstedt	Jul 1999	A
5928201	Poulsen et al.	Jul 1999	A
5931814	Alex et al.	Aug 1999	A
5932175	Knute et al.	Aug 1999	A
5933121	Rainhart et al.	Aug 1999	A
5935099	Peterson et al.	Aug 1999	A
5945963	Leisten	Aug 1999	A
5947911	Wong et al.	Sep 1999	A
5947934	Hansen et al.	Sep 1999	A
5951530	Steengaard et al.	Sep 1999	A
5957889	Poulsen et al.	Sep 1999	A
5957890	Mann et al.	Sep 1999	A
5961492	Kriesel et al.	Oct 1999	A
5965848	Altschul et al.	Oct 1999	A
5971941	Simons et al.	Oct 1999	A
5984894	Poulsen et al.	Nov 1999	A
5984897	Petersen et al.	Nov 1999	A
5993423	Choi	Nov 1999	A
5997475	Bortz	Dec 1999	A
5997501	Gross et al.	Dec 1999	A
6003736	Ljunggren	Dec 1999	A
6005151	Herrmann et al.	Dec 1999	A
6010485	Buch-Rasmussen et al.	Jan 2000	A
6017318	Gauthier et al.	Jan 2000	A
6019747	McPhee	Feb 2000	A
6023251	Koo et al.	Feb 2000	A
6024539	Blomquist	Feb 2000	A
6027826	Derochemont et al.	Feb 2000	A
6028568	Asakura et al.	Feb 2000	A
6031445	Marty et al.	Feb 2000	A
6032059	Henning et al.	Feb 2000	A
6033377	Rasmussen et al.	Mar 2000	A
6036924	Simons et al.	Mar 2000	A
6040578	Malin et al.	Mar 2000	A
6040805	Huynh et al.	Mar 2000	A
6045537	Klitmose	Apr 2000	A
6046707	Gaughan et al.	Apr 2000	A
6049727	Crothall	Apr 2000	A
6050978	Orr et al.	Apr 2000	A
6052040	Hino	Apr 2000	A
6056728	Von Schuckmann	May 2000	A
6058934	Sullivan	May 2000	A
6066103	Duchon et al.	May 2000	A
6071292	Makower et al.	Jun 2000	A
6072180	Kramer et al.	Jun 2000	A
6074372	Hansen	Jun 2000	A
6077055	Vilks	Jun 2000	A
6090092	Fowles et al.	Jul 2000	A
6101406	Hacker et al.	Aug 2000	A
6102872	Doneen et al.	Aug 2000	A
6106498	Friedli et al.	Aug 2000	A
6110149	Klitgaard et al.	Aug 2000	A
6111544	Dakeya et al.	Aug 2000	A
6115673	Malin et al.	Sep 2000	A
6123827	Wong et al.	Sep 2000	A
6124134	Stark	Sep 2000	A
6126595	Amano et al.	Oct 2000	A
6126637	Kriesel et al.	Oct 2000	A
6127061	Shun et al.	Oct 2000	A
6128519	Say	Oct 2000	A
6142939	Eppstein et al.	Nov 2000	A
6143164	Heller et al.	Nov 2000	A
6143432	De et al.	Nov 2000	A
6154176	Fathy et al.	Nov 2000	A
6156014	Petersen et al.	Dec 2000	A
6157041	Thomas et al.	Dec 2000	A
6161028	Braig et al.	Dec 2000	A
6162639	Douglas	Dec 2000	A
6171276	Lippe et al.	Jan 2001	B1
6174300	Kriesel et al.	Jan 2001	B1
6176004	Rainhart et al.	Jan 2001	B1
6181297	Leisten	Jan 2001	B1
6188368	Koriyama et al.	Feb 2001	B1
6190359	Heruth	Feb 2001	B1
6195049	Kim et al.	Feb 2001	B1
6196046	Braig et al.	Mar 2001	B1
6200287	Keller et al.	Mar 2001	B1
6200293	Kriesel et al.	Mar 2001	B1
6200338	Solomon et al.	Mar 2001	B1
6204203	Narwankar et al.	Mar 2001	B1
6208843	Huang et al.	Mar 2001	B1
6214629	Freitag et al.	Apr 2001	B1
6222489	Tsuru et al.	Apr 2001	B1
6226082	Roe	May 2001	B1
6231540	Smedegaard	May 2001	B1
6233471	Berner et al.	May 2001	B1
6244776	Wiley	Jun 2001	B1
6248067	Causey et al.	Jun 2001	B1
6248090	Jensen et al.	Jun 2001	B1
6248093	Moberg	Jun 2001	B1
6251113	Appelbaum et al.	Jun 2001	B1
6261065	Nayak et al.	Jul 2001	B1
6262798	Shepherd et al.	Jul 2001	B1
6266020	Chang	Jul 2001	B1
6269340	Ford et al.	Jul 2001	B1
6270455	Brown	Aug 2001	B1
6271045	Douglas et al.	Aug 2001	B1
6277098	Klitmose et al.	Aug 2001	B1
6280381	Malin et al.	Aug 2001	B1
6285448	Kuenstner	Sep 2001	B1
6292440	Lee	Sep 2001	B1
6300894	Lynch et al.	Oct 2001	B1
6302855	Lav et al.	Oct 2001	B1
6302869	Klitgaard	Oct 2001	B1
6309370	Haim et al.	Oct 2001	B1
6312888	Wong et al.	Nov 2001	B1
6320547	Fathy et al.	Nov 2001	B1
6323549	Derochemont et al.	Nov 2001	B1
6334851	Hayes et al.	Jan 2002	B1
6363609	Pickren	Apr 2002	B1
6368314	Kipfer et al.	Apr 2002	B1
6375627	Mauze et al.	Apr 2002	B1
6375638	Nason et al.	Apr 2002	B2
6379301	Worthington et al.	Apr 2002	B1
6379339	Klitgaard et al.	Apr 2002	B1
6381496	Meadows et al.	Apr 2002	B1
6397098	Uber et al.	May 2002	B1
6402689	Scarantino et al.	Jun 2002	B1
6404098	Kayama et al.	Jun 2002	B1
6413244	Bestetti et al.	Jul 2002	B1
6427088	Bowman et al.	Jul 2002	B1
D461241	Moberg et al.	Aug 2002	S
D461891	Moberg	Aug 2002	S
6434528	Sanders	Aug 2002	B1
6436072	Kullas et al.	Aug 2002	B1
6461329	Van et al.	Oct 2002	B1
6461331	Van Antwerp	Oct 2002	B1
6470279	Samsoondar	Oct 2002	B1
6474219	Klitmose et al.	Nov 2002	B2
6475196	Vachon	Nov 2002	B1
6477065	Parks	Nov 2002	B2
6477901	Tadigadapa et al.	Nov 2002	B1
6484044	Lilienfeld-Toal	Nov 2002	B1
6485461	Mason et al.	Nov 2002	B1
6485462	Kriesel	Nov 2002	B1
6491656	Morris	Dec 2002	B1
6491684	Joshi et al.	Dec 2002	B1
6492949	Breglia et al.	Dec 2002	B1
6496149	Birnbaum et al.	Dec 2002	B1
6501415	Viana et al.	Dec 2002	B1
6508788	Preuthun	Jan 2003	B2
6512937	Blank et al.	Jan 2003	B2
6520936	Mann	Feb 2003	B1
6524280	Hansen et al.	Feb 2003	B2
6525509	Petersson et al.	Feb 2003	B1
6527744	Kriesel et al.	Mar 2003	B1
6528809	Thomas et al.	Mar 2003	B1
6533183	Aasmul et al.	Mar 2003	B2
6537249	Kriesell et al.	Mar 2003	B2
6537251	Klitmose	Mar 2003	B2
6537268	Gibson et al.	Mar 2003	B1
6540260	Tan	Apr 2003	B1
6540672	Simonsen et al.	Apr 2003	B1
6541820	Bol	Apr 2003	B1
6544212	Galley et al.	Apr 2003	B2
6544229	Danby et al.	Apr 2003	B1
6546268	Ishikawa et al.	Apr 2003	B1
6546269	Kurnik	Apr 2003	B1
6547764	Larsen et al.	Apr 2003	B2
6551276	Mann et al.	Apr 2003	B1
6552693	Leisten	Apr 2003	B1
6553841	Blouch	Apr 2003	B1
6554798	Mann et al.	Apr 2003	B1
6554800	Nezhadian et al.	Apr 2003	B1
6556850	Braig et al.	Apr 2003	B1
D474778	Barnes	May 2003	S
6558320	Causey et al.	May 2003	B1
6558345	Houben et al.	May 2003	B1
6558351	Steil et al.	May 2003	B1
6559735	Hoang et al.	May 2003	B1
6560471	Heller et al.	May 2003	B1
6561978	Conn et al.	May 2003	B1
6562001	Lebel et al.	May 2003	B2
6562011	Buch-Rasmussen et al.	May 2003	B1
6562014	Lin et al.	May 2003	B2
6564105	Starkweather et al.	May 2003	B2
6569115	Barker et al.	May 2003	B1
6569125	Jepson et al.	May 2003	B2
6569126	Poulsen et al.	May 2003	B1
6571128	Lebel et al.	May 2003	B2
6572542	Houben et al.	Jun 2003	B1
6572545	Knobbe et al.	Jun 2003	B2
6574490	Abbink et al.	Jun 2003	B2
6575905	Knobbe et al.	Jun 2003	B2
6577899	Lebel et al.	Jun 2003	B2
6580934	Braig et al.	Jun 2003	B1
6582404	Klitgaard et al.	Jun 2003	B1
6583699	Yokoyama	Jun 2003	B2
6585644	Lebel et al.	Jul 2003	B2
6585699	Ljunggreen et al.	Jul 2003	B2
6587199	Luu	Jul 2003	B1
6589229	Connelly et al.	Jul 2003	B1
6595956	Gross et al.	Jul 2003	B1
6599281	Struys et al.	Jul 2003	B1
6605067	Larsen	Aug 2003	B1
6605072	Struys et al.	Aug 2003	B2
6611419	Chakravorty	Aug 2003	B1
6613019	Munk	Sep 2003	B2
6618603	Varalli et al.	Sep 2003	B2
6620750	Kim et al.	Sep 2003	B2
6633772	Ford et al.	Oct 2003	B2
6635958	Bates et al.	Oct 2003	B2
6639556	Baba	Oct 2003	B2
6641533	Causey et al.	Nov 2003	B2
6642908	Pleva et al.	Nov 2003	B2
6645142	Braig et al.	Nov 2003	B2
6648821	Lebel et al.	Nov 2003	B2
6650303	Kim et al.	Nov 2003	B2
6650951	Jones et al.	Nov 2003	B1
6653091	Dunn et al.	Nov 2003	B1
6656158	Mahoney et al.	Dec 2003	B2
6656159	Flaherty	Dec 2003	B2
6659948	Lebel et al.	Dec 2003	B2
6659978	Kasuga et al.	Dec 2003	B1
6659980	Moberg et al.	Dec 2003	B2
6662030	Khalil et al.	Dec 2003	B2
6663602	Moeller	Dec 2003	B2
6668196	Villegas et al.	Dec 2003	B1
6669663	Thompson	Dec 2003	B1
6669668	Kleeman et al.	Dec 2003	B1
6669669	Flaherty et al.	Dec 2003	B2
6670497	Tashino et al.	Dec 2003	B2
6678542	Braig et al.	Jan 2004	B2
6680700	Hilgers	Jan 2004	B2
6683576	Hilgers	Jan 2004	B2
6685674	Douglas et al.	Feb 2004	B2
6686406	Tomomatsu et al.	Feb 2004	B2
6687546	Lebel et al.	Feb 2004	B2
6689100	Connelly et al.	Feb 2004	B2
6690192	Wing	Feb 2004	B1
6690336	Leisten et al.	Feb 2004	B1
6691043	Ribeiro, Jr.	Feb 2004	B2
6692457	Flaherty	Feb 2004	B2
6692472	Hansen et al.	Feb 2004	B2
6694191	Starkweather et al.	Feb 2004	B2
6697605	Atokawa et al.	Feb 2004	B1
6699218	Flaherty et al.	Mar 2004	B2
6699221	Vaillancourt	Mar 2004	B2
6702779	Connelly et al.	Mar 2004	B2
6715516	Ohms et al.	Apr 2004	B2
6716198	Larsen	Apr 2004	B2
6718189	Rohrscheib et al.	Apr 2004	B2
6720926	Killen et al.	Apr 2004	B2
6721582	Trepagnier et al.	Apr 2004	B2
6723072	Flaherty et al.	Apr 2004	B2
6723077	Pickup et al.	Apr 2004	B2
6727785	Killen et al.	Apr 2004	B2
6728560	Kollias et al.	Apr 2004	B2
6731244	Killen et al.	May 2004	B2
6731248	Killen et al.	May 2004	B2
6733446	Lebel et al.	May 2004	B2
6733890	Imanaka et al.	May 2004	B2
6736796	Shekalim	May 2004	B2
6740059	Flaherty	May 2004	B2
6740072	Starkweather et al.	May 2004	B2
6740075	Lebel et al.	May 2004	B2
6741148	Killen et al.	May 2004	B2
6742249	DeRochemont et al.	Jun 2004	B2
6743744	Kim et al.	Jun 2004	B1
6744350	Blomquist	Jun 2004	B2
6749587	Flaherty	Jun 2004	B2
6750740	Killen et al.	Jun 2004	B2
6750820	Killen et al.	Jun 2004	B2
6751490	Esenaliev et al.	Jun 2004	B2
6752785	Van et al.	Jun 2004	B2
6752787	Causey et al.	Jun 2004	B1
6753745	Killen et al.	Jun 2004	B2
6753814	Killen et al.	Jun 2004	B2
6758810	Lebel et al.	Jul 2004	B2
6758835	Close et al.	Jul 2004	B2
6761286	Py et al.	Jul 2004	B2
6762237	Glatkowski et al.	Jul 2004	B2
6768425	Flaherty et al.	Jul 2004	B2
6780156	Haueter et al.	Aug 2004	B2
6786246	Ohms et al.	Sep 2004	B2
6786890	Preuthun et al.	Sep 2004	B2
6787181	Uchiyama et al.	Sep 2004	B2
6791496	Killen et al.	Sep 2004	B1
6796957	Carpenter et al.	Sep 2004	B2
6796970	Klitmose et al.	Sep 2004	B1
6799149	Hartlaub	Sep 2004	B2
6809653	Mann et al.	Oct 2004	B1
6810290	Lebel et al.	Oct 2004	B2
6811533	Lebel et al.	Nov 2004	B2
6811534	Bowman et al.	Nov 2004	B2
6813519	Lebel et al.	Nov 2004	B2
6826031	Nagai et al.	Nov 2004	B2
6827702	Lebel et al.	Dec 2004	B2
6830558	Flaherty et al.	Dec 2004	B2
6830623	Hayashi et al.	Dec 2004	B2
6837858	Cunningham et al.	Jan 2005	B2
6837988	Leong et al.	Jan 2005	B2
6846288	Nagar et al.	Jan 2005	B2
6852104	Blomquist	Feb 2005	B2
6853288	Ahn et al.	Feb 2005	B2
6854620	Ramey	Feb 2005	B2
6854653	Eilersen	Feb 2005	B2
6855129	Jensen et al.	Feb 2005	B2
6858892	Yamagata	Feb 2005	B2
6862534	Sterling et al.	Mar 2005	B2
6864848	Sievenpiper	Mar 2005	B2
6865408	Abbink et al.	Mar 2005	B1
6871396	Sugaya et al.	Mar 2005	B2
6872200	Mann et al.	Mar 2005	B2
6873268	Lebel et al.	Mar 2005	B2
6878132	Kipfer	Apr 2005	B2
6878871	Scher et al.	Apr 2005	B2
6883778	Newton et al.	Apr 2005	B1
6890291	Robinson et al.	May 2005	B2
6893415	Madsen et al.	May 2005	B2
6899695	Herrera	May 2005	B2
6899699	Enggaard	May 2005	B2
6905989	Ellis et al.	Jun 2005	B2
6906674	McKinzie et al.	Jun 2005	B2
6914566	Beard	Jul 2005	B2
6919119	Kalkan et al.	Jul 2005	B2
6922590	Whitehurst	Jul 2005	B1
6923763	Kovatchev et al.	Aug 2005	B1
6925393	Kalatz et al.	Aug 2005	B1
6928298	Furutani et al.	Aug 2005	B2
6936006	Sabra	Aug 2005	B2
6936029	Mann et al.	Aug 2005	B2
6943430	Kwon	Sep 2005	B2
6943731	Killen et al.	Sep 2005	B2
6945961	Miller et al.	Sep 2005	B2
6949081	Chance	Sep 2005	B1
6950708	Bowman et al.	Sep 2005	B2
6958809	Sterling et al.	Oct 2005	B2
6960192	Flaherty et al.	Nov 2005	B1
6963259	Killen et al.	Nov 2005	B2
6979326	Mann et al.	Dec 2005	B2
6989891	Braig et al.	Jan 2006	B2
6990366	Say et al.	Jan 2006	B2
6997911	Klitmose	Feb 2006	B2
6997920	Mann et al.	Feb 2006	B2
7002436	Ma et al.	Feb 2006	B2
7005078	Van et al.	Feb 2006	B2
7008399	Larsen et al.	Mar 2006	B2
7008404	Nakajima	Mar 2006	B2
7009180	Sterling et al.	Mar 2006	B2
7014625	Bengtsson	Mar 2006	B2
7016713	Gardner et al.	Mar 2006	B2
7018360	Flaherty et al.	Mar 2006	B2
7025743	Mann et al.	Apr 2006	B2
7025744	Utterberg et al.	Apr 2006	B2
7027848	Robinson et al.	Apr 2006	B2
7029455	Flaherty	Apr 2006	B2
7043288	Davis et al.	May 2006	B2
7047637	DeRochemont et al.	May 2006	B2
7054836	Christensen et al.	May 2006	B2
7060059	Keith et al.	Jun 2006	B2
7060350	Takaya et al.	Jun 2006	B2
7061593	Braig et al.	Jun 2006	B2
7066910	Bauhahn et al.	Jun 2006	B2
7070580	Nielsen	Jul 2006	B2
7096124	Sterling et al.	Aug 2006	B2
7098803	Mann et al.	Aug 2006	B2
7104972	Moller et al.	Sep 2006	B2
7109878	Mann et al.	Sep 2006	B2
7115205	Robinson et al.	Oct 2006	B2
7116949	Irie et al.	Oct 2006	B2
7123964	Betzold et al.	Oct 2006	B2
7133329	Skyggebjerg et al.	Nov 2006	B2
7137694	Ferran et al.	Nov 2006	B2
7139593	Kavak et al.	Nov 2006	B2
7139598	Hull et al.	Nov 2006	B2
7144384	Gorman et al.	Dec 2006	B2
7160272	Eyal et al.	Jan 2007	B1
7171252	Scarantino et al.	Jan 2007	B1
7172572	Diamond et al.	Feb 2007	B2
7179226	Crothall et al.	Feb 2007	B2
7190988	Say et al.	Mar 2007	B2
7204823	Estes et al.	Apr 2007	B2
7220240	Struys et al.	May 2007	B2
7230316	Yamazaki et al.	Jun 2007	B2
7232423	Mernoee	Jun 2007	B2
7248912	Gough et al.	Jul 2007	B2
7267665	Steil et al.	Sep 2007	B2
7271912	Sterling et al.	Sep 2007	B2
7278983	Ireland et al.	Oct 2007	B2
7291107	Hellwig et al.	Nov 2007	B2
7291497	Holmes et al.	Nov 2007	B2
7291782	Sager et al.	Nov 2007	B2
7303549	Flaherty et al.	Dec 2007	B2
7303622	Loch et al.	Dec 2007	B2
7303922	Jeng et al.	Dec 2007	B2
7354420	Steil et al.	Apr 2008	B2
7388202	Sterling et al.	Jun 2008	B2
7402153	Steil et al.	Jul 2008	B2
7404796	Ginsberg	Jul 2008	B2
7405698	De Rochemont	Jul 2008	B2
7429255	Thompson	Sep 2008	B2
7460130	Salganicoff	Dec 2008	B2
7481787	Gable et al.	Jan 2009	B2
7491187	Van et al.	Feb 2009	B2
7494481	Moberg et al.	Feb 2009	B2
7500949	Gottlieb et al.	Mar 2009	B2
7509156	Flanders	Mar 2009	B2
D590415	Ball et al.	Apr 2009	S
7522124	Smith et al.	Apr 2009	B2
7547281	Hayes et al.	Jun 2009	B2
7553281	Hellwig et al.	Jun 2009	B2
7553512	Kodas et al.	Jun 2009	B2
7564887	Wang et al.	Jul 2009	B2
7569030	Lebel et al.	Aug 2009	B2
7569050	Moberg et al.	Aug 2009	B2
7570980	Ginsberg	Aug 2009	B2
7591801	Brauker et al.	Sep 2009	B2
7595623	Bennett	Sep 2009	B2
7597682	Moberg	Oct 2009	B2
7608042	Goldberger et al.	Oct 2009	B2
7641649	Moberg et al.	Jan 2010	B2
7651845	Doyle et al.	Jan 2010	B2
7652901	Kirchmeier et al.	Jan 2010	B2
7654982	Carlisle et al.	Feb 2010	B2
7670288	Sher	Mar 2010	B2
7680529	Kroll	Mar 2010	B2
D614634	Nilsen	Apr 2010	S
7708717	Estes et al.	May 2010	B2
7714794	Tavassoli Hozouri	May 2010	B2
7734323	Blomquist et al.	Jun 2010	B2
7763917	De Rochemont	Jul 2010	B2
7766829	Sloan et al.	Aug 2010	B2
7771391	Carter	Aug 2010	B2
7785258	Braig et al.	Aug 2010	B2
7785313	Mastrototaro	Aug 2010	B2
7789859	Estes et al.	Sep 2010	B2
7794426	Briones et al.	Sep 2010	B2
7806853	Wittmann et al.	Oct 2010	B2
7806854	Damiano et al.	Oct 2010	B2
7812774	Friman et al.	Oct 2010	B2
7815602	Mann et al.	Oct 2010	B2
7819843	Mann et al.	Oct 2010	B2
7828528	Estes et al.	Nov 2010	B2
7850641	Lebel et al.	Dec 2010	B2
7904061	Zaffino et al.	Mar 2011	B1
7918825	O'Connor et al.	Apr 2011	B2
7938797	Estes	May 2011	B2
7938801	Hawkins et al.	May 2011	B2
7946985	Mastrototaro et al.	May 2011	B2
D640269	Chen	Jun 2011	S
7959598	Estes	Jun 2011	B2
7967812	Jasperson et al.	Jun 2011	B2
7972296	Braig et al.	Jul 2011	B2
7976492	Brauker et al.	Jul 2011	B2
8029459	Rush et al.	Oct 2011	B2
8062249	Wilinska et al.	Nov 2011	B2
8066805	Zuercher et al.	Nov 2011	B2
8069690	Desantolo et al.	Dec 2011	B2
8105268	Lebel et al.	Jan 2012	B2
8114023	Ward et al.	Feb 2012	B2
8114489	Nemat-Nasser et al.	Feb 2012	B2
8152789	Starkweather et al.	Apr 2012	B2
8178457	De Rochemont	May 2012	B2
8193873	Kato et al.	Jun 2012	B2
8206296	Jennewine	Jun 2012	B2
8206350	Mann et al.	Jun 2012	B2
8208984	Blomquist et al.	Jun 2012	B2
8221345	Blomquist	Jul 2012	B2
8221385	Estes	Jul 2012	B2
8226556	Hayes et al.	Jul 2012	B2
8246540	Ginsberg	Aug 2012	B2
8251907	Sterling et al.	Aug 2012	B2
8262616	Grant et al.	Sep 2012	B2
8267893	Moberg et al.	Sep 2012	B2
8267921	Yodfat et al.	Sep 2012	B2
8273052	Damiano et al.	Sep 2012	B2
D669165	Sims et al.	Oct 2012	S
8282626	Wenger et al.	Oct 2012	B2
8287487	Estes	Oct 2012	B2
8318154	Frost et al.	Nov 2012	B2
8348844	Kunjan et al.	Jan 2013	B2
8348886	Kanderian et al.	Jan 2013	B2
8348923	Kanderian et al.	Jan 2013	B2
8350657	DeRochemont	Jan 2013	B2
8352011	Van et al.	Jan 2013	B2
8354294	De et al.	Jan 2013	B2
8372039	Mernoe et al.	Feb 2013	B2
D677685	Simmons et al.	Mar 2013	S
8417311	Rule	Apr 2013	B2
8430847	Mernoe et al.	Apr 2013	B2
8439834	Schmelzeisen-Redeker et al.	May 2013	B2
8439897	Yodfat et al.	May 2013	B2
8449524	Braig et al.	May 2013	B2
8452359	Rebec et al.	May 2013	B2
8454576	Mastrototaro et al.	Jun 2013	B2
8460231	Brauker et al.	Jun 2013	B2
8467972	Rush	Jun 2013	B2
8467980	Campbell et al.	Jun 2013	B2
8475409	Tsoukalis	Jul 2013	B2
8478557	Hayter et al.	Jul 2013	B2
8480655	Jasperson et al.	Jul 2013	B2
D688686	Rhee et al.	Aug 2013	S
8547239	Peatfield et al.	Oct 2013	B2
8548544	Kircher et al.	Oct 2013	B2
8548552	Tsoukalis	Oct 2013	B2
8551045	Sie et al.	Oct 2013	B2
8560082	Wei	Oct 2013	B2
8560131	Haueter et al.	Oct 2013	B2
8562558	Kamath et al.	Oct 2013	B2
8562587	Kovatchev et al.	Oct 2013	B2
8568713	Frost et al.	Oct 2013	B2
D693837	Bouchier	Nov 2013	S
8579854	Budiman et al.	Nov 2013	B2
8579879	Palerm et al.	Nov 2013	B2
8585591	Sloan et al.	Nov 2013	B2
8585593	Kovatchev et al.	Nov 2013	B2
8585637	Wilinska et al.	Nov 2013	B2
8585638	Blomquist	Nov 2013	B2
8593819	De Rochemont	Nov 2013	B2
D695757	Ray et al.	Dec 2013	S
8597274	Sloan et al.	Dec 2013	B2
8615366	Galley et al.	Dec 2013	B2
8622988	Hayter	Jan 2014	B2
8679016	Mastrototaro et al.	Mar 2014	B2
8679060	Mernoe et al.	Mar 2014	B2
8690820	Cinar et al.	Apr 2014	B2
8694115	Goetz et al.	Apr 2014	B2
8706691	McDaniel et al.	Apr 2014	B2
8715839	De Rochemont	May 2014	B2
8718949	Blomquist et al.	May 2014	B2
8721585	Brauker et al.	May 2014	B2
8727982	Jennewine	May 2014	B2
8734422	Hayter	May 2014	B2
8734428	Blomquist	May 2014	B2
8747315	Brauker et al.	Jun 2014	B2
8762070	Doyle et al.	Jun 2014	B2
8771222	Kanderian et al.	Jul 2014	B2
8777896	Starkweather et al.	Jul 2014	B2
8777924	Kanderian et al.	Jul 2014	B2
8784364	Kamen et al.	Jul 2014	B2
8784369	Starkweather et al.	Jul 2014	B2
8784370	Lebel et al.	Jul 2014	B2
8790294	Estes	Jul 2014	B2
D710879	Elston et al.	Aug 2014	S
8795224	Starkweather et al.	Aug 2014	B2
8795252	Hayter	Aug 2014	B2
8808230	Rotstein	Aug 2014	B2
8810394	Kalpin	Aug 2014	B2
D714822	Capua et al.	Oct 2014	S
D715315	Wood	Oct 2014	S
D715815	Bortman et al.	Oct 2014	S
8852141	Mhatre et al.	Oct 2014	B2
8876755	Taub et al.	Nov 2014	B2
8882741	Brauker et al.	Nov 2014	B2
D718779	Hang et al.	Dec 2014	S
D720366	Hiltunen et al.	Dec 2014	S
8903501	Perryman	Dec 2014	B2
8919180	Gottlieb et al.	Dec 2014	B2
8920401	Brauker et al.	Dec 2014	B2
D720765	Xie et al.	Jan 2015	S
8926585	Brauker et al.	Jan 2015	B2
8939935	O'Connor et al.	Jan 2015	B2
8945094	Nordh	Feb 2015	B2
8956291	Valk et al.	Feb 2015	B2
8956321	Dejournett	Feb 2015	B2
8977504	Hovorka	Mar 2015	B2
8992475	Mann et al.	Mar 2015	B2
D726760	Yokota et al.	Apr 2015	S
D727928	Allison et al.	Apr 2015	S
D730378	Xiong et al.	May 2015	S
9034323	Frost et al.	May 2015	B2
D733175	Bae	Jun 2015	S
9050413	Brauker et al.	Jun 2015	B2
9056165	Steil et al.	Jun 2015	B2
9056168	Kircher et al.	Jun 2015	B2
9061097	Holt et al.	Jun 2015	B2
D734356	Xiong et al.	Jul 2015	S
9078963	Estes	Jul 2015	B2
9089305	Hovorka	Jul 2015	B2
D736811	Teichner et al.	Aug 2015	S
D737305	Scazafavo et al.	Aug 2015	S
D737831	Lee	Sep 2015	S
D737832	Lim et al.	Sep 2015	S
D738901	Amin	Sep 2015	S
D740301	Soegiono et al.	Oct 2015	S
D740308	Kim et al.	Oct 2015	S
D740311	Drozd et al.	Oct 2015	S
D741354	Lee et al.	Oct 2015	S
D741359	Ji-Hye et al.	Oct 2015	S
9149233	Kamath et al.	Oct 2015	B2
9155843	Brauker et al.	Oct 2015	B2
9171343	Fischell et al.	Oct 2015	B1
D743431	Pal et al.	Nov 2015	S
D743991	Pal et al.	Nov 2015	S
9180224	Moseley et al.	Nov 2015	B2
9180244	Anderson et al.	Nov 2015	B2
9192716	Jugl et al.	Nov 2015	B2
D744514	Shin et al.	Dec 2015	S
D744517	Pal et al.	Dec 2015	S
D745032	Pal et al.	Dec 2015	S
D745034	Pal et al.	Dec 2015	S
D745035	Pal et al.	Dec 2015	S
D746827	Jung et al.	Jan 2016	S
D746828	Arai et al.	Jan 2016	S
D747352	Lee et al.	Jan 2016	S
9233204	Booth et al.	Jan 2016	B2
D749097	Zou et al.	Feb 2016	S
D749118	Wang	Feb 2016	S
9247901	Kamath et al.	Feb 2016	B2
D751100	Lindn et al.	Mar 2016	S
D752604	Zhang	Mar 2016	S
D753134	Vazquez	Apr 2016	S
D754718	Zhou	Apr 2016	S
9314566	Wenger et al.	Apr 2016	B2
9320471	Hayes et al.	Apr 2016	B2
D755193	Sun et al.	May 2016	S
D755799	Finnis et al.	May 2016	S
D755820	Wang	May 2016	S
D756387	Chang et al.	May 2016	S
D757032	Sabia et al.	May 2016	S
D757035	Raskin et al.	May 2016	S
9333298	Kim et al.	May 2016	B2
D758391	Suarez	Jun 2016	S
D758422	Zhao	Jun 2016	S
D759032	Amin et al.	Jun 2016	S
D759078	Iwamoto	Jun 2016	S
D759678	Jung et al.	Jun 2016	S
D759687	Chang et al.	Jun 2016	S
D761812	Motamedi	Jul 2016	S
D763308	Wang et al.	Aug 2016	S
D763868	Lee et al.	Aug 2016	S
D765110	Liang	Aug 2016	S
D765124	Minks-Brown et al.	Aug 2016	S
9402950	Dilanni et al.	Aug 2016	B2
9415157	Mann et al.	Aug 2016	B2
D765707	Gomez	Sep 2016	S
D766286	Lee et al.	Sep 2016	S
D767586	Kwon et al.	Sep 2016	S
D768154	Kim et al.	Oct 2016	S
D768188	Ll et al.	Oct 2016	S
D768660	Wielgosz	Oct 2016	S
D768685	Lee et al.	Oct 2016	S
D769315	Scotti	Oct 2016	S
9474855	McCann et al.	Oct 2016	B2
D770507	Umezawa et al.	Nov 2016	S
D770515	Cho et al.	Nov 2016	S
D771073	Choi et al.	Nov 2016	S
D771076	Butcher et al.	Nov 2016	S
D771690	Yin et al.	Nov 2016	S
D772911	Lee et al.	Nov 2016	S
9480796	Starkweather et al.	Nov 2016	B2
9486172	Cobelli et al.	Nov 2016	B2
9486571	Rosinko	Nov 2016	B2
9486578	Finan et al.	Nov 2016	B2
D773531	Toth et al.	Dec 2016	S
D775184	Song et al.	Dec 2016	S
D775196	Huang et al.	Dec 2016	S
9520649	De Rochemont	Dec 2016	B2
D775658	Luo et al.	Jan 2017	S
D776126	Lai et al.	Jan 2017	S
D776687	Wick et al.	Jan 2017	S
D777191	Polimeni	Jan 2017	S
D777758	Kisselev et al.	Jan 2017	S
9561324	Estes	Feb 2017	B2
9579456	Budiman et al.	Feb 2017	B2
D781323	Green et al.	Mar 2017	S
D781781	Schimmoeller, Jr.	Mar 2017	S
D781877	Ko et al.	Mar 2017	S
D781878	Butcher et al.	Mar 2017	S
D781879	Butcher et al.	Mar 2017	S
D781903	Reichle et al.	Mar 2017	S
D781905	Nakaguchi et al.	Mar 2017	S
D782506	Kim et al.	Mar 2017	S
D783672	Rajasankar et al.	Apr 2017	S
D785010	Bachman et al.	Apr 2017	S
D785656	Bramer et al.	May 2017	S
D786278	Motamedi	May 2017	S
D786898	Hall	May 2017	S
D788126	Evnin et al.	May 2017	S
9656017	Greene	May 2017	B2
D788621	Shallice et al.	Jun 2017	S
D788652	Mutsuro et al.	Jun 2017	S
D789402	Dye et al.	Jun 2017	S
D789967	Kaplan et al.	Jun 2017	S
D789982	Christiana et al.	Jun 2017	S
D790560	Inose et al.	Jun 2017	S
D791781	Donarski et al.	Jul 2017	S
D791805	Segars	Jul 2017	S
D791812	Bistoni et al.	Jul 2017	S
D793412	Chaudhri et al.	Aug 2017	S
D795886	Ng et al.	Aug 2017	S
D795891	Kohan et al.	Aug 2017	S
D795900	Bischoff et al.	Aug 2017	S
D795906	Butrick	Aug 2017	S
D795927	Bischoff et al.	Aug 2017	S
9743224	San et al.	Aug 2017	B2
D796530	McMillan et al.	Sep 2017	S
D796540	McLean et al.	Sep 2017	S
D797116	Chapman et al.	Sep 2017	S
D797763	Kim et al.	Sep 2017	S
D797774	Park et al.	Sep 2017	S
D797797	Gandhi et al.	Sep 2017	S
D798310	Golden et al.	Sep 2017	S
D798311	Golden et al.	Sep 2017	S
D799536	Eder	Oct 2017	S
D800765	Stoksik	Oct 2017	S
D800769	Hennessy et al.	Oct 2017	S
D801383	Park et al.	Oct 2017	S
D802011	Friedman et al.	Nov 2017	S
D802088	Bos et al.	Nov 2017	S
D803232	Leigh et al.	Nov 2017	S
D803242	Mizono et al.	Nov 2017	S
D804502	Amini et al.	Dec 2017	S
D805525	Dascola et al.	Dec 2017	S
D806716	Pahwa et al.	Jan 2018	S
D807376	Mizono et al.	Jan 2018	S
D807400	Lagreca	Jan 2018	S
D807910	Graham et al.	Jan 2018	S
D807918	Cohen et al.	Jan 2018	S
D807919	Cohen et al.	Jan 2018	S
D808423	Jiang et al.	Jan 2018	S
D808974	Chiappone et al.	Jan 2018	S
D808983	Narinedhat et al.	Jan 2018	S
9857090	Golden et al.	Jan 2018	B2
9878097	Estes	Jan 2018	B2
D810116	McLean et al.	Feb 2018	S
D810771	Gandhi et al.	Feb 2018	S
9907515	Doyle et al.	Mar 2018	B2
D815131	Thompson et al.	Apr 2018	S
D816090	Stonecipher et al.	Apr 2018	S
D817339	Nanjappan et al.	May 2018	S
D818491	Timmer et al.	May 2018	S
D819057	Huang	May 2018	S
D819059	O'Toole	May 2018	S
9968729	Estes	May 2018	B2
9980140	Spencer et al.	May 2018	B1
9984773	Gondhalekar et al.	May 2018	B2
D820311	Cabrera et al.	Jun 2018	S
D820862	Alfonzo et al.	Jun 2018	S
D822034	Clymer et al.	Jul 2018	S
D822677	Weaver et al.	Jul 2018	S
D822684	Clausen-Stuck et al.	Jul 2018	S
D822692	Loychik et al.	Jul 2018	S
D823862	Chung et al.	Jul 2018	S
D824400	Chang et al.	Jul 2018	S
D824951	Kolbrener et al.	Aug 2018	S
D826956	Pillalamarri et al.	Aug 2018	S
D826957	Pillalamarri et al.	Aug 2018	S
D828381	Lee et al.	Sep 2018	S
D829732	Jeffrey et al.	Oct 2018	S
D830374	Leonard et al.	Oct 2018	S
D830384	Lepine et al.	Oct 2018	S
D830385	Lepine et al.	Oct 2018	S
D830407	Kisielius et al.	Oct 2018	S
D831033	Leonard et al.	Oct 2018	S
D833469	Coleman et al.	Nov 2018	S
D834601	Felt	Nov 2018	S
D835132	Ito et al.	Dec 2018	S
D835145	Cashner et al.	Dec 2018	S
D835147	Kisielius et al.	Dec 2018	S
D835651	Bao	Dec 2018	S
D835666	Saleh et al.	Dec 2018	S
D836123	Pillalamarri et al.	Dec 2018	S
D837807	Baber et al.	Jan 2019	S
D838731	Pillalamarri et al.	Jan 2019	S
D840418	Saad et al.	Feb 2019	S
D840419	Saad et al.	Feb 2019	S
D844022	Amin	Mar 2019	S
D845317	Wellmeier et al.	Apr 2019	S
10248839	Levy et al.	Apr 2019	B2
D848459	Li	May 2019	S
D851099	Uppala et al.	Jun 2019	S
D851658	Pillalamarri et al.	Jun 2019	S
10335464	Michelich et al.	Jul 2019	B1
10449294	Estes	Oct 2019	B1
D865795	Koo	Nov 2019	S
D872746	Laborde	Jan 2020	S
D874471	Pillalamarri et al.	Feb 2020	S
D875114	Clediere	Feb 2020	S
10569015	Estes	Feb 2020	B2
10583250	Mazlish et al.	Mar 2020	B2
D880498	Shahidi et al.	Apr 2020	S
D888070	Yusupov et al.	Jun 2020	S
10737015	Estes	Aug 2020	B2
10737024	Schmid	Aug 2020	B2
D904426	Debashish	Dec 2020	S
D911353	Sanchez et al.	Feb 2021	S
D914031	Ding et al.	Mar 2021	S
D916729	Gabriel et al.	Apr 2021	S
D916870	Hemsley	Apr 2021	S
D916878	Kim et al.	Apr 2021	S
10987468	Mazlish et al.	Apr 2021	B2
D918261	Ramamurthy et al.	May 2021	S
D920351	Zhang	May 2021	S
D923033	Smith et al.	Jun 2021	S
D927533	Clymer	Aug 2021	S
D938447	Holland	Dec 2021	S
11197964	Sjolund et al.	Dec 2021	B2
11260169	Estes	Mar 2022	B2
D954078	Rahate et al.	Jun 2022	S
20010003542	Kita	Jun 2001	A1
20010021803	Blank et al.	Sep 2001	A1
20010034023	Stanton et al.	Oct 2001	A1
20010034502	Moberg et al.	Oct 2001	A1
20010041869	Causey et al.	Nov 2001	A1
20010048969	Constantino et al.	Dec 2001	A1
20010051377	Hammer et al.	Dec 2001	A1
20010053895	Vaillancourt	Dec 2001	A1
20010056258	Evans	Dec 2001	A1
20010056262	Cabiri et al.	Dec 2001	A1
20020010401	Bushmakin et al.	Jan 2002	A1
20020010423	Gross et al.	Jan 2002	A1
20020013784	Swanson	Jan 2002	A1
20020016534	Trepagnier et al.	Feb 2002	A1
20020016568	Lebel et al.	Feb 2002	A1
20020032402	Daoud et al.	Mar 2002	A1
20020040208	Flaherty et al.	Apr 2002	A1
20020046315	Miller et al.	Apr 2002	A1
20020047768	Duffy	Apr 2002	A1
20020055845	Ueda et al.	May 2002	A1
20020070983	Kozub et al.	Jun 2002	A1
20020072720	Hague et al.	Jun 2002	A1
20020107476	Mann et al.	Aug 2002	A1
20020123740	Flaherty et al.	Sep 2002	A1
20020128543	Leonhardt	Sep 2002	A1
20020147423	Burbank et al.	Oct 2002	A1
20020155425	Han et al.	Oct 2002	A1
20020156462	Stultz	Oct 2002	A1
20020161288	Shin et al.	Oct 2002	A1
20020164973	Janik et al.	Nov 2002	A1
20020173769	Gray et al.	Nov 2002	A1
20020190818	Endou et al.	Dec 2002	A1
20030023148	Lorenz et al.	Jan 2003	A1
20030023152	Abbink et al.	Jan 2003	A1
20030034124	Sugaya et al.	Feb 2003	A1
20030040715	D'Antonio et al.	Feb 2003	A1
20030050621	Lebel et al.	Mar 2003	A1
20030055380	Flaherty	Mar 2003	A1
20030060692	Ruchti et al.	Mar 2003	A1
20030065308	Lebel et al.	Apr 2003	A1
20030086073	Braig et al.	May 2003	A1
20030086074	Braig et al.	May 2003	A1
20030086075	Braig et al.	May 2003	A1
20030088238	Poulsen et al.	May 2003	A1
20030090649	Sterling et al.	May 2003	A1
20030100040	Bonnecaze et al.	May 2003	A1
20030104982	Wittmann et al.	Jun 2003	A1
20030121055	Kaminski et al.	Jun 2003	A1
20030122647	Ou	Jul 2003	A1
20030125672	Adair et al.	Jul 2003	A1
20030135388	Martucci et al.	Jul 2003	A1
20030144582	Cohen et al.	Jul 2003	A1
20030148024	Kodas et al.	Aug 2003	A1
20030161744	Vilks et al.	Aug 2003	A1
20030163097	Fleury et al.	Aug 2003	A1
20030170436	Sumi et al.	Sep 2003	A1
20030175806	Rule et al.	Sep 2003	A1
20030195404	Knobbe et al.	Oct 2003	A1
20030198558	Nason et al.	Oct 2003	A1
20030208113	Mault	Nov 2003	A1
20030208154	Close et al.	Nov 2003	A1
20030212379	Bylund et al.	Nov 2003	A1
20030216627	Lorenz et al.	Nov 2003	A1
20030216683	Shekalim	Nov 2003	A1
20030216686	Lynch et al.	Nov 2003	A1
20030220605	Bowman et al.	Nov 2003	A1
20030221621	Pokharna et al.	Dec 2003	A1
20030236498	Gross et al.	Dec 2003	A1
20040001027	Killen et al.	Jan 2004	A1
20040006316	Patton	Jan 2004	A1
20040010207	Flaherty et al.	Jan 2004	A1
20040019325	Shekalim	Jan 2004	A1
20040034295	Salganicoff	Feb 2004	A1
20040045879	Shults et al.	Mar 2004	A1
20040051368	Caputo et al.	Mar 2004	A1
20040064088	Gorman et al.	Apr 2004	A1
20040064096	Flaherty et al.	Apr 2004	A1
20040064259	Haaland et al.	Apr 2004	A1
20040068224	Couvillon et al.	Apr 2004	A1
20040068230	Estes et al.	Apr 2004	A1
20040069004	Gist et al.	Apr 2004	A1
20040069044	Lavi et al.	Apr 2004	A1
20040078028	Flaherty et al.	Apr 2004	A1
20040087894	Flaherty	May 2004	A1
20040087904	Langley et al.	May 2004	A1
20040092865	Flaherty et al.	May 2004	A1
20040092878	Flaherty	May 2004	A1
20040097796	Berman et al.	May 2004	A1
20040115068	Hansen et al.	Jun 2004	A1
20040116847	Wall	Jun 2004	A1
20040116866	Gorman et al.	Jun 2004	A1
20040122353	Shahmirian et al.	Jun 2004	A1
20040127844	Flaherty	Jul 2004	A1
20040133166	Moberg et al.	Jul 2004	A1
20040147034	Gore et al.	Jul 2004	A1
20040153032	Garribotto et al.	Aug 2004	A1
20040158207	Hunn et al.	Aug 2004	A1
20040171983	Sparks et al.	Sep 2004	A1
20040176720	Kipfer	Sep 2004	A1
20040176727	Shekalim	Sep 2004	A1
20040187952	Jones	Sep 2004	A1
20040203357	Nassimi	Oct 2004	A1
20040204673	Flaherty	Oct 2004	A1
20040204744	Penner et al.	Oct 2004	A1
20040204868	Maynard et al.	Oct 2004	A1
20040215492	Choi	Oct 2004	A1
20040220551	Flaherty et al.	Nov 2004	A1
20040235446	Flaherty et al.	Nov 2004	A1
20040241736	Hendee et al.	Dec 2004	A1
20040249308	Forssell	Dec 2004	A1
20040260233	Garibotto et al.	Dec 2004	A1
20050003470	Nelson et al.	Jan 2005	A1
20050010165	Hickle	Jan 2005	A1
20050020980	Inoue et al.	Jan 2005	A1
20050021005	Flaherty et al.	Jan 2005	A1
20050021104	DiLorenzo	Jan 2005	A1
20050022274	Campbell et al.	Jan 2005	A1
20050033148	Haueter et al.	Feb 2005	A1
20050038332	Saidara et al.	Feb 2005	A1
20050049179	Davidson et al.	Mar 2005	A1
20050065464	Talbot et al.	Mar 2005	A1
20050065760	Murtfeldt et al.	Mar 2005	A1
20050075624	Miesel	Apr 2005	A1
20050090808	Malave et al.	Apr 2005	A1
20050090851	Devlin	Apr 2005	A1
20050095063	Fathallah et al.	May 2005	A1
20050101933	Marrs et al.	May 2005	A1
20050105095	Pesach et al.	May 2005	A1
20050107743	Fangrow, Jr.	May 2005	A1
20050113745	Stultz	May 2005	A1
20050124866	Elaz et al.	Jun 2005	A1
20050134609	Yu	Jun 2005	A1
20050137530	Campbell et al.	Jun 2005	A1
20050137573	McLaughlin	Jun 2005	A1
20050160858	Mernoe	Jul 2005	A1
20050171503	Van et al.	Aug 2005	A1
20050171512	Flaherty	Aug 2005	A1
20050182306	Sloan	Aug 2005	A1
20050182366	Vogt et al.	Aug 2005	A1
20050192494	Ginsberg	Sep 2005	A1
20050192557	Brauker et al.	Sep 2005	A1
20050197621	Poulsen et al.	Sep 2005	A1
20050203360	Brauker et al.	Sep 2005	A1
20050203461	Flaherty et al.	Sep 2005	A1
20050215982	Malave et al.	Sep 2005	A1
20050222645	Malave et al.	Oct 2005	A1
20050234404	Vilks et al.	Oct 2005	A1
20050238507	Diianni et al.	Oct 2005	A1
20050240544	Kil et al.	Oct 2005	A1
20050245878	Mernoe et al.	Nov 2005	A1
20050251097	Mernoe	Nov 2005	A1
20050261660	Choi	Nov 2005	A1
20050262451	Remignanti et al.	Nov 2005	A1
20050267402	Stewart et al.	Dec 2005	A1
20050272640	Doyle et al.	Dec 2005	A1
20050273059	Mernoe et al.	Dec 2005	A1
20050277890	Stewart et al.	Dec 2005	A1
20050277912	John	Dec 2005	A1
20060009727	O'Mahony et al.	Jan 2006	A1
20060036214	Mogensen et al.	Feb 2006	A1
20060041229	Garibotto et al.	Feb 2006	A1
20060042633	Bishop et al.	Mar 2006	A1
20060064053	Bollish et al.	Mar 2006	A1
20060069351	Safabash et al.	Mar 2006	A9
20060069382	Pedersen	Mar 2006	A1
20060074381	Malave et al.	Apr 2006	A1
20060075269	Liong et al.	Apr 2006	A1
20060079765	Neer et al.	Apr 2006	A1
20060079809	Goldberger et al.	Apr 2006	A1
20060086994	Viefers et al.	Apr 2006	A1
20060095014	Ethelfeld	May 2006	A1
20060100494	Kroll	May 2006	A1
20060125654	Liao et al.	Jun 2006	A1
20060134323	O'Brien	Jun 2006	A1
20060134491	Hilchenko et al.	Jun 2006	A1
20060135913	Ethelfeld	Jun 2006	A1
20060142698	Ethelfeld	Jun 2006	A1
20060151545	Imhof et al.	Jul 2006	A1
20060167350	Monfre et al.	Jul 2006	A1
20060173410	Moberg et al.	Aug 2006	A1
20060178633	Garibotto et al.	Aug 2006	A1
20060184104	Cheney et al.	Aug 2006	A1
20060184119	Remde et al.	Aug 2006	A1
20060189925	Gable et al.	Aug 2006	A1
20060189926	Hall et al.	Aug 2006	A1
20060197015	Sterling et al.	Sep 2006	A1
20060200070	Callicoat et al.	Sep 2006	A1
20060200073	Radmer et al.	Sep 2006	A1
20060204535	Johnson	Sep 2006	A1
20060206054	Shekalim	Sep 2006	A1
20060214511	Dayan	Sep 2006	A1
20060229531	Goldberger et al.	Oct 2006	A1
20060247574	Maule et al.	Nov 2006	A1
20060247581	Pedersen et al.	Nov 2006	A1
20060253085	Geismar et al.	Nov 2006	A1
20060253086	Moberg et al.	Nov 2006	A1
20060258973	Volt	Nov 2006	A1
20060258976	Shturman et al.	Nov 2006	A1
20060264835	Nielsen et al.	Nov 2006	A1
20060264890	Moberg et al.	Nov 2006	A1
20060264894	Moberg et al.	Nov 2006	A1
20060264895	Flanders	Nov 2006	A1
20060270983	Lord et al.	Nov 2006	A1
20060276771	Galley et al.	Dec 2006	A1
20060282290	Flaherty et al.	Dec 2006	A1
20070016127	Staib et al.	Jan 2007	A1
20070060796	Kim	Mar 2007	A1
20070060869	Tolle et al.	Mar 2007	A1
20070060870	Tolle et al.	Mar 2007	A1
20070060872	Hall et al.	Mar 2007	A1
20070073228	Mernoe et al.	Mar 2007	A1
20070073235	Estes et al.	Mar 2007	A1
20070073236	Mernoe et al.	Mar 2007	A1
20070078818	Zivitz et al.	Apr 2007	A1
20070079836	Reghabi et al.	Apr 2007	A1
20070083160	Hall et al.	Apr 2007	A1
20070088271	Richards	Apr 2007	A1
20070093750	Jan et al.	Apr 2007	A1
20070093786	Goldsmith et al.	Apr 2007	A1
20070100222	Mastrototaro et al.	May 2007	A1
20070100635	Mahajan et al.	May 2007	A1
20070106135	Sloan et al.	May 2007	A1
20070106218	Yodfat et al.	May 2007	A1
20070112298	Mueller et al.	May 2007	A1
20070116601	Patton	May 2007	A1
20070118364	Wise et al.	May 2007	A1
20070118405	Campbell et al.	May 2007	A1
20070123819	Mernoe et al.	May 2007	A1
20070124002	Estes et al.	May 2007	A1
20070129690	Rosenblatt et al.	Jun 2007	A1
20070142720	Ridder et al.	Jun 2007	A1
20070142776	Kovelman et al.	Jun 2007	A9
20070155307	Ng et al.	Jul 2007	A1
20070156092	Estes et al.	Jul 2007	A1
20070156094	Safabash et al.	Jul 2007	A1
20070166170	Nason et al.	Jul 2007	A1
20070166453	Van et al.	Jul 2007	A1
20070167905	Estes et al.	Jul 2007	A1
20070167912	Causey et al.	Jul 2007	A1
20070169607	Keller et al.	Jul 2007	A1
20070173761	Kanderian et al.	Jul 2007	A1
20070173974	Lin	Jul 2007	A1
20070179352	Randlov et al.	Aug 2007	A1
20070179444	Causey et al.	Aug 2007	A1
20070191702	Yodfat et al.	Aug 2007	A1
20070191716	Goldberger et al.	Aug 2007	A1
20070197163	Robertson	Aug 2007	A1
20070219432	Thompson	Sep 2007	A1
20070219480	Kamen et al.	Sep 2007	A1
20070225675	Robinson et al.	Sep 2007	A1
20070233521	Wehba et al.	Oct 2007	A1
20070239116	Follman et al.	Oct 2007	A1
20070244381	Robinson et al.	Oct 2007	A1
20070248238	Abreu	Oct 2007	A1
20070249007	Rosero	Oct 2007	A1
20070252774	Qi et al.	Nov 2007	A1
20070255250	Moberg et al.	Nov 2007	A1
20070259768	Kear et al.	Nov 2007	A1
20070264707	Liederman et al.	Nov 2007	A1
20070282269	Carter et al.	Dec 2007	A1
20070282299	Hellwig	Dec 2007	A1
20070287931	DiLorenzo	Dec 2007	A1
20070287985	Estes et al.	Dec 2007	A1
20070293843	Ireland et al.	Dec 2007	A1
20080009824	Moberg et al.	Jan 2008	A1
20080015422	Wessel	Jan 2008	A1
20080027574	Thomas	Jan 2008	A1
20080031481	Warren et al.	Feb 2008	A1
20080033272	Gough et al.	Feb 2008	A1
20080033320	Racchini et al.	Feb 2008	A1
20080045891	Maule et al.	Feb 2008	A1
20080051697	Mounce et al.	Feb 2008	A1
20080051698	Mounce et al.	Feb 2008	A1
20080051714	Moberg et al.	Feb 2008	A1
20080051716	Stutz	Feb 2008	A1
20080051730	Bikovsky	Feb 2008	A1
20080051738	Griffin	Feb 2008	A1
20080051764	Dent et al.	Feb 2008	A1
20080058625	McGarraugh et al.	Mar 2008	A1
20080065050	Sparks et al.	Mar 2008	A1
20080071157	McGarraugh et al.	Mar 2008	A1
20080071158	McGarraugh et al.	Mar 2008	A1
20080077081	Mounce et al.	Mar 2008	A1
20080078400	Martens et al.	Apr 2008	A1
20080097289	Steil et al.	Apr 2008	A1
20080097326	Moberg et al.	Apr 2008	A1
20080097375	Bikovsky	Apr 2008	A1
20080097381	Moberg et al.	Apr 2008	A1
20080103022	Dvorak et al.	May 2008	A1
20080109050	John	May 2008	A1
20080114304	Nalesso et al.	May 2008	A1
20080125700	Moberg et al.	May 2008	A1
20080125701	Moberg et al.	May 2008	A1
20080129535	Thompson et al.	Jun 2008	A1
20080132880	Buchman	Jun 2008	A1
20080160492	Campbell et al.	Jul 2008	A1
20080161664	Mastrototaro et al.	Jul 2008	A1
20080172026	Blomquist	Jul 2008	A1
20080172027	Blomquist	Jul 2008	A1
20080172028	Blomquist	Jul 2008	A1
20080172029	Blomquist	Jul 2008	A1
20080177149	Weinert et al.	Jul 2008	A1
20080183060	Steil et al.	Jul 2008	A1
20080188796	Steil et al.	Aug 2008	A1
20080198012	Kamen	Aug 2008	A1
20080200838	Goldberger et al.	Aug 2008	A1
20080201325	Doniger et al.	Aug 2008	A1
20080206067	De et al.	Aug 2008	A1
20080208113	Damiano et al.	Aug 2008	A1
20080208627	Skyggebjerg	Aug 2008	A1
20080214919	Harmon et al.	Sep 2008	A1
20080215035	Yodfat et al.	Sep 2008	A1
20080228056	Blomquist et al.	Sep 2008	A1
20080234630	Iddan et al.	Sep 2008	A1
20080249386	Besterman et al.	Oct 2008	A1
20080255516	Yodfat et al.	Oct 2008	A1
20080269585	Ginsberg	Oct 2008	A1
20080269683	Bikovsky	Oct 2008	A1
20080269687	Chong et al.	Oct 2008	A1
20080269714	Mastrototaro et al.	Oct 2008	A1
20080269723	Mastrototaro et al.	Oct 2008	A1
20080287906	Burkholz et al.	Nov 2008	A1
20080294094	Mhatre et al.	Nov 2008	A1
20080294109	Estes et al.	Nov 2008	A1
20080294142	Patel et al.	Nov 2008	A1
20080300572	Rankers et al.	Dec 2008	A1
20080306434	Dobbles et al.	Dec 2008	A1
20080306444	Brister et al.	Dec 2008	A1
20080312512	Brukalo et al.	Dec 2008	A1
20080312634	Helmerson et al.	Dec 2008	A1
20080319381	Yodfat et al.	Dec 2008	A1
20080319383	Byland et al.	Dec 2008	A1
20080319384	Yodfat et al.	Dec 2008	A1
20080319394	Yodfat et al.	Dec 2008	A1
20080319414	Yodfat et al.	Dec 2008	A1
20080319416	Yodfat et al.	Dec 2008	A1
20090006061	Thukral et al.	Jan 2009	A1
20090018406	Yodfat et al.	Jan 2009	A1
20090030398	Yodfat et al.	Jan 2009	A1
20090036753	King	Feb 2009	A1
20090036760	Hayter	Feb 2009	A1
20090036870	Mounce et al.	Feb 2009	A1
20090043240	Robinson et al.	Feb 2009	A1
20090043291	Thompson	Feb 2009	A1
20090048584	Thompson	Feb 2009	A1
20090054753	Robinson et al.	Feb 2009	A1
20090069743	Krishnamoorthy et al.	Mar 2009	A1
20090069745	Estes et al.	Mar 2009	A1
20090069746	Miller et al.	Mar 2009	A1
20090069749	Miller et al.	Mar 2009	A1
20090069784	Estes et al.	Mar 2009	A1
20090069785	Miller et al.	Mar 2009	A1
20090069787	Estes et al.	Mar 2009	A1
20090076453	Mejlhede et al.	Mar 2009	A1
20090076849	Diller	Mar 2009	A1
20090082728	Bikovsky	Mar 2009	A1
20090093756	Minaie et al.	Apr 2009	A1
20090099507	Koops	Apr 2009	A1
20090099521	Gravesen et al.	Apr 2009	A1
20090105573	Malecha	Apr 2009	A1
20090105636	Hayter et al.	Apr 2009	A1
20090112333	Sahai	Apr 2009	A1
20090118664	Estes et al.	May 2009	A1
20090131861	Braig et al.	May 2009	A1
20090143916	Boll et al.	Jun 2009	A1
20090156922	Goldberger et al.	Jun 2009	A1
20090156924	Shariati et al.	Jun 2009	A1
20090156990	Wenger et al.	Jun 2009	A1
20090163781	Say et al.	Jun 2009	A1
20090164190	Hayter	Jun 2009	A1
20090177142	Blomquist et al.	Jul 2009	A1
20090177154	Blomquist	Jul 2009	A1
20090192722	Shariati et al.	Jul 2009	A1
20090198191	Chong et al.	Aug 2009	A1
20090198215	Chong et al.	Aug 2009	A1
20090198350	Thiele	Aug 2009	A1
20090212966	Panduro	Aug 2009	A1
20090221890	Saffer et al.	Sep 2009	A1
20090228214	Say et al.	Sep 2009	A1
20090318791	Kaastrup	Dec 2009	A1
20090326343	Gable et al.	Dec 2009	A1
20090326472	Carter et al.	Dec 2009	A1
20100010330	Rankers et al.	Jan 2010	A1
20100017141	Campbell et al.	Jan 2010	A1
20100036326	Matusch	Feb 2010	A1
20100057040	Hayter	Mar 2010	A1
20100057041	Hayter	Mar 2010	A1
20100064243	Buck et al.	Mar 2010	A1
20100077198	Buck et al.	Mar 2010	A1
20100094078	Weston	Apr 2010	A1
20100114026	Karratt et al.	May 2010	A1
20100121167	McGarraugh	May 2010	A1
20100137784	Cefai et al.	Jun 2010	A1
20100145272	Cefai et al.	Jun 2010	A1
20100152658	Hanson et al.	Jun 2010	A1
20100165795	Elder et al.	Jul 2010	A1
20100168538	Keenan et al.	Jul 2010	A1
20100168820	Maniak et al.	Jul 2010	A1
20100174228	Buckingham et al.	Jul 2010	A1
20100174229	Hsu et al.	Jul 2010	A1
20100174266	Estes	Jul 2010	A1
20100179409	Kamath et al.	Jul 2010	A1
20100185183	Alme et al.	Jul 2010	A1
20100211003	Sundar et al.	Aug 2010	A1
20100211005	Edwards et al.	Aug 2010	A1
20100241066	Hansen et al.	Sep 2010	A1
20100249530	Rankers et al.	Sep 2010	A1
20100262117	Magni et al.	Oct 2010	A1
20100262434	Shaya	Oct 2010	A1
20100273738	Valcke et al.	Oct 2010	A1
20100286601	Yodfat et al.	Nov 2010	A1
20100286653	Kubel et al.	Nov 2010	A1
20100298685	Hayter et al.	Nov 2010	A1
20100298765	Budiman et al.	Nov 2010	A1
20100324382	Cantwell et al.	Dec 2010	A1
20100324977	Dragt	Dec 2010	A1
20100325864	Briones et al.	Dec 2010	A1
20110009813	Rankers	Jan 2011	A1
20110015511	Bousamra et al.	Jan 2011	A1
20110021584	Berggren et al.	Jan 2011	A1
20110028817	Jin et al.	Feb 2011	A1
20110040247	Mandro et al.	Feb 2011	A1
20110049394	De Rochemont	Mar 2011	A1
20110054390	Searle et al.	Mar 2011	A1
20110054399	Chong et al.	Mar 2011	A1
20110065224	Bollman et al.	Mar 2011	A1
20110071464	Palerm	Mar 2011	A1
20110071765	Yodfat et al.	Mar 2011	A1
20110098637	Hill	Apr 2011	A1
20110098674	Vicente et al.	Apr 2011	A1
20110105955	Yudovsky et al.	May 2011	A1
20110106050	Yodfat et al.	May 2011	A1
20110118699	Yodfat et al.	May 2011	A1
20110124996	Reinke et al.	May 2011	A1
20110130716	Estes et al.	Jun 2011	A1
20110144586	Michaud et al.	Jun 2011	A1
20110160652	Yodfat et al.	Jun 2011	A1
20110163880	Halff et al.	Jul 2011	A1
20110178472	Cabiri	Jul 2011	A1
20110190694	Lanier et al.	Aug 2011	A1
20110199194	Waldock et al.	Aug 2011	A1
20110202005	Yodfat et al.	Aug 2011	A1
20110218495	Remde	Sep 2011	A1
20110224523	Budiman	Sep 2011	A1
20110230833	Landman et al.	Sep 2011	A1
20110251509	Beyhan et al.	Oct 2011	A1
20110313390	Roy et al.	Dec 2011	A1
20110313680	Doyle et al.	Dec 2011	A1
20110316562	Cefai et al.	Dec 2011	A1
20110319813	Kamen et al.	Dec 2011	A1
20120003935	Lydon et al.	Jan 2012	A1
20120010594	Holt et al.	Jan 2012	A1
20120016304	Patel et al.	Jan 2012	A1
20120029468	Diperna et al.	Feb 2012	A1
20120030393	Ganesh et al.	Feb 2012	A1
20120046606	Arefieg	Feb 2012	A1
20120053556	Lee	Mar 2012	A1
20120065894	Tubb et al.	Mar 2012	A1
20120078067	Kovatchev et al.	Mar 2012	A1
20120078161	Masterson et al.	Mar 2012	A1
20120078181	Smith et al.	Mar 2012	A1
20120101451	Boit et al.	Apr 2012	A1
20120123234	Atlas et al.	May 2012	A1
20120124521	Guo	May 2012	A1
20120150446	Chang et al.	Jun 2012	A1
20120150556	Galasso et al.	Jun 2012	A1
20120172694	Desborough et al.	Jul 2012	A1
20120172802	Blomquist	Jul 2012	A1
20120185267	Kamen et al.	Jul 2012	A1
20120190955	Rao et al.	Jul 2012	A1
20120197207	Stefanski	Aug 2012	A1
20120203085	Rebec	Aug 2012	A1
20120203178	Tverskoy	Aug 2012	A1
20120203467	Kamath et al.	Aug 2012	A1
20120209208	Stefanski	Aug 2012	A1
20120215087	Cobelli et al.	Aug 2012	A1
20120225134	Komorowski	Sep 2012	A1
20120226259	Yodfat et al.	Sep 2012	A1
20120227737	Mastrototaro et al.	Sep 2012	A1
20120232520	Sloan et al.	Sep 2012	A1
20120238851	Kamen et al.	Sep 2012	A1
20120238853	Arefieg	Sep 2012	A1
20120238999	Estes et al.	Sep 2012	A1
20120245448	Shariati et al.	Sep 2012	A1
20120245556	Kovatchev et al.	Sep 2012	A1
20120245855	Kamath et al.	Sep 2012	A1
20120246106	Atlas et al.	Sep 2012	A1
20120250449	Nakano	Oct 2012	A1
20120259191	Shariati et al.	Oct 2012	A1
20120271655	Knobel et al.	Oct 2012	A1
20120277668	Chawla	Nov 2012	A1
20120277723	Skladnev et al.	Nov 2012	A1
20120282111	Nip et al.	Nov 2012	A1
20120283694	Yodfat et al.	Nov 2012	A1
20120289931	Robinson et al.	Nov 2012	A1
20120295550	Wilson et al.	Nov 2012	A1
20120302991	Blomquist et al.	Nov 2012	A1
20120323590	Udani	Dec 2012	A1
20120330270	Colton	Dec 2012	A1
20130030358	Yodfat et al.	Jan 2013	A1
20130046281	Javitt	Feb 2013	A1
20130053818	Estes	Feb 2013	A1
20130053819	Estes	Feb 2013	A1
20130053820	Estes et al.	Feb 2013	A1
20130102867	Desborough et al.	Apr 2013	A1
20130116649	Breton et al.	May 2013	A1
20130138205	Kushwaha et al.	May 2013	A1
20130158503	Kanderian et al.	Jun 2013	A1
20130159456	Daoud et al.	Jun 2013	A1
20130165041	Bukovjan et al.	Jun 2013	A1
20130172695	Nielsen et al.	Jul 2013	A1
20130172710	Mears et al.	Jul 2013	A1
20130178791	Javitt	Jul 2013	A1
20130204186	Moore et al.	Aug 2013	A1
20130204202	Trombly et al.	Aug 2013	A1
20130218126	Hayter et al.	Aug 2013	A1
20130231642	Doyle et al.	Sep 2013	A1
20130237932	Thueer et al.	Sep 2013	A1
20130245545	Arnold et al.	Sep 2013	A1
20130245563	Mercer et al.	Sep 2013	A1
20130245604	Kouyoumjian et al.	Sep 2013	A1
20130253284	Fraier et al.	Sep 2013	A1
20130253418	Kamath et al.	Sep 2013	A1
20130253472	Cabiri	Sep 2013	A1
20130261406	Rebec et al.	Oct 2013	A1
20130275139	Coleman	Oct 2013	A1
20130281965	Kamen et al.	Oct 2013	A1
20130296792	Cabiri	Nov 2013	A1
20130296823	Melker et al.	Nov 2013	A1
20130297334	Galasso et al.	Nov 2013	A1
20130298080	Griffin et al.	Nov 2013	A1
20130317753	Kamen et al.	Nov 2013	A1
20130332874	Rosinko et al.	Dec 2013	A1
20130338576	O'Connor et al.	Dec 2013	A1
20130338629	Agrawal et al.	Dec 2013	A1
20130338630	Agrawal et al.	Dec 2013	A1
20130345663	Agrawal et al.	Dec 2013	A1
20130346858	Neyrinck	Dec 2013	A1
20140005633	Finan	Jan 2014	A1
20140018730	Mueller-Pathle	Jan 2014	A1
20140025015	Cross et al.	Jan 2014	A1
20140031759	Kouyoumjian et al.	Jan 2014	A1
20140032549	McDaniel et al.	Jan 2014	A1
20140039383	Dobbles et al.	Feb 2014	A1
20140052091	Dobbles et al.	Feb 2014	A1
20140052092	Dobbles et al.	Feb 2014	A1
20140052093	Dobbles et al.	Feb 2014	A1
20140052094	Dobbles et al.	Feb 2014	A1
20140052095	Dobbles et al.	Feb 2014	A1
20140066859	Ogawa et al.	Mar 2014	A1
20140066884	Keenan et al.	Mar 2014	A1
20140066885	Keenan et al.	Mar 2014	A1
20140066886	Roy et al.	Mar 2014	A1
20140066887	Mastrototaro et al.	Mar 2014	A1
20140066888	Parikh et al.	Mar 2014	A1
20140066889	Grosman et al.	Mar 2014	A1
20140066890	Sloan et al.	Mar 2014	A1
20140066892	Keenan et al.	Mar 2014	A1
20140074033	Sonderegger et al.	Mar 2014	A1
20140088428	Yang et al.	Mar 2014	A1
20140088557	Mernoe et al.	Mar 2014	A1
20140094766	Estes et al.	Apr 2014	A1
20140107607	Estes	Apr 2014	A1
20140108046	Echeverria et al.	Apr 2014	A1
20140114278	Dobbles et al.	Apr 2014	A1
20140121635	Hayter	May 2014	A1
20140127048	Diianni et al.	May 2014	A1
20140128705	Mazlish	May 2014	A1
20140128803	Dobbles et al.	May 2014	A1
20140128839	Diianni et al.	May 2014	A1
20140129951	Amin et al.	May 2014	A1
20140135880	Baumgartner et al.	May 2014	A1
20140142508	Diianni et al.	May 2014	A1
20140146202	Boss et al.	May 2014	A1
20140171901	Langsdorf et al.	Jun 2014	A1
20140180203	Budiman et al.	Jun 2014	A1
20140180240	Finan et al.	Jun 2014	A1
20140200426	Taub et al.	Jul 2014	A1
20140200559	Doyle et al.	Jul 2014	A1
20140228627	Soffer et al.	Aug 2014	A1
20140228668	Wakizaka et al.	Aug 2014	A1
20140230021	Birtwhistle et al.	Aug 2014	A1
20140235981	Hayter	Aug 2014	A1
20140249500	Estes	Sep 2014	A1
20140276553	Rosinko et al.	Sep 2014	A1
20140276554	Finan et al.	Sep 2014	A1
20140276555	Morales	Sep 2014	A1
20140276556	Saint et al.	Sep 2014	A1
20140276583	Chen et al.	Sep 2014	A1
20140278123	Prodhom et al.	Sep 2014	A1
20140309615	Mazlish	Oct 2014	A1
20140316379	Sonderegger et al.	Oct 2014	A1
20140323959	Ebel et al.	Oct 2014	A1
20140325065	Birtwhistle et al.	Oct 2014	A1
20150018633	Kovachev et al.	Jan 2015	A1
20150025329	Amarasingham et al.	Jan 2015	A1
20150025471	Enggaard	Jan 2015	A1
20150025495	Peyser	Jan 2015	A1
20150025503	Searle et al.	Jan 2015	A1
20150030641	Anderson et al.	Jan 2015	A1
20150041498	Kakiuchi et al.	Feb 2015	A1
20150045737	Stefanski	Feb 2015	A1
20150073337	Saint et al.	Mar 2015	A1
20150080789	Estes et al.	Mar 2015	A1
20150120317	Mayou et al.	Apr 2015	A1
20150120323	Galasso et al.	Apr 2015	A1
20150134265	Kohlbrecher et al.	May 2015	A1
20150134353	Ferrell et al.	May 2015	A1
20150136336	Huang	May 2015	A1
20150148774	Yao	May 2015	A1
20150157794	Roy et al.	Jun 2015	A1
20150164414	Matthews	Jun 2015	A1
20150165119	Palerm et al.	Jun 2015	A1
20150173674	Hayes et al.	Jun 2015	A1
20150193585	Sunna	Jul 2015	A1
20150202386	Brady et al.	Jul 2015	A1
20150205509	Scriven et al.	Jul 2015	A1
20150205511	Vinna et al.	Jul 2015	A1
20150213217	Amarasingham et al.	Jul 2015	A1
20150217051	Mastrototaro et al.	Aug 2015	A1
20150217052	Keenan et al.	Aug 2015	A1
20150217053	Booth et al.	Aug 2015	A1
20150265767	Vazquez et al.	Sep 2015	A1
20150265768	Vazquez et al.	Sep 2015	A1
20150301691	Qin	Oct 2015	A1
20150306314	Doyle et al.	Oct 2015	A1
20150314062	Blomquist et al.	Nov 2015	A1
20150320933	Estes	Nov 2015	A1
20150328402	Nogueira et al.	Nov 2015	A1
20150331995	Zhao et al.	Nov 2015	A1
20150351671	Vanslyke et al.	Dec 2015	A1
20150351672	Vanslyke et al.	Dec 2015	A1
20150351683	Brauker et al.	Dec 2015	A1
20150352282	Mazlish	Dec 2015	A1
20150352283	Galasso	Dec 2015	A1
20150356250	Polimeni	Dec 2015	A1
20150366945	Greene	Dec 2015	A1
20160000998	Estes	Jan 2016	A1
20160015891	Papiorek	Jan 2016	A1
20160019352	Cohen et al.	Jan 2016	A1
20160030669	Harris et al.	Feb 2016	A1
20160038673	Morales	Feb 2016	A1
20160038689	Lee et al.	Feb 2016	A1
20160051749	Istoc	Feb 2016	A1
20160082187	Schaible et al.	Mar 2016	A1
20160082188	Blomquist et al.	Mar 2016	A1
20160089494	Guerrini	Mar 2016	A1
20160158438	Monirabbasi et al.	Jun 2016	A1
20160162662	Monirabbasi et al.	Jun 2016	A1
20160175520	Palerm et al.	Jun 2016	A1
20160213841	Geismar et al.	Jul 2016	A1
20160220181	Rigoard et al.	Aug 2016	A1
20160228641	Gescheit et al.	Aug 2016	A1
20160243318	Despa et al.	Aug 2016	A1
20160256087	Doyle et al.	Sep 2016	A1
20160256629	Grosman et al.	Sep 2016	A1
20160259889	Murtha et al.	Sep 2016	A1
20160287512	Cooper et al.	Oct 2016	A1
20160302054	Kimura et al.	Oct 2016	A1
20160331310	Kovatchev	Nov 2016	A1
20160354543	Cinar et al.	Dec 2016	A1
20170007882	Werner	Jan 2017	A1
20170021096	Cole et al.	Jan 2017	A1
20170049386	Abraham et al.	Feb 2017	A1
20170131887	Kim et al.	May 2017	A1
20170143899	Gondhalekar et al.	May 2017	A1
20170143900	Rioux et al.	May 2017	A1
20170156682	Doyle et al.	Jun 2017	A1
20170173261	O'Connor et al.	Jun 2017	A1
20170182248	Rosinko	Jun 2017	A1
20170188943	Braig et al.	Jul 2017	A1
20170189614	Mazlish et al.	Jul 2017	A1
20170189625	Cirillo et al.	Jul 2017	A1
20170203036	Mazlish et al.	Jul 2017	A1
20170216524	Haider et al.	Aug 2017	A1
20170239415	Hwang et al.	Aug 2017	A1
20170258987	Caspers	Sep 2017	A1
20170281877	Marlin et al.	Oct 2017	A1
20170296746	Chen et al.	Oct 2017	A1
20170311903	Davis et al.	Nov 2017	A1
20170347971	Davis et al.	Dec 2017	A1
20170348482	Duke et al.	Dec 2017	A1
20180036495	Searle et al.	Feb 2018	A1
20180040255	Freeman et al.	Feb 2018	A1
20180075200	Davis et al.	Mar 2018	A1
20180075201	Davis et al.	Mar 2018	A1
20180075202	Davis et al.	Mar 2018	A1
20180092576	Ambrsio	Apr 2018	A1
20180126073	Wu et al.	May 2018	A1
20180169334	Grosman et al.	Jun 2018	A1
20180200434	Mazlish et al.	Jul 2018	A1
20180200438	Mazlish et al.	Jul 2018	A1
20180200441	Desborough et al.	Jul 2018	A1
20180204636	Edwards et al.	Jul 2018	A1
20180277253	Gondhalekar et al.	Sep 2018	A1
20180289891	Finan et al.	Oct 2018	A1
20180296757	Finan et al.	Oct 2018	A1
20180307515	Meller et al.	Oct 2018	A1
20180342317	Skirble et al.	Nov 2018	A1
20180369479	Hayter et al.	Dec 2018	A1
20190076600	Grosman et al.	Mar 2019	A1
20190095052	De et al.	Mar 2019	A1
20190132801	Kamath et al.	May 2019	A1
20190184091	Sjolund et al.	Jun 2019	A1
20190240403	Palerm et al.	Aug 2019	A1
20190290844	Monirabbasi et al.	Sep 2019	A1
20190321545	Saint	Oct 2019	A1
20190336683	O'Connor et al.	Nov 2019	A1
20190336684	O'Connor et al.	Nov 2019	A1
20190348157	Booth et al.	Nov 2019	A1
20190374714	Rioux et al.	Dec 2019	A1
20200001006	Pizzochero et al.	Jan 2020	A1
20200046268	Patek et al.	Feb 2020	A1
20200101222	Lintereur et al.	Apr 2020	A1
20200101223	Lintereur et al.	Apr 2020	A1
20200101225	O'Connor et al.	Apr 2020	A1
20200113515	O'Connor et al.	Apr 2020	A1
20200219625	Kahlbaugh	Jul 2020	A1
20200342974	Chen et al.	Oct 2020	A1
20210050085	Hayter et al.	Feb 2021	A1
20210098105	Lee et al.	Apr 2021	A1
20220023536	Graham et al.	Jan 2022	A1
20220105270	Doyle et al.	Apr 2022	A1

Foreign Referenced Citations (249)

Number	Date	Country
2015200834	Mar 2015	AU
2015301146	Mar 2017	AU
1040271	Oct 1978	CA
2543545	May 2005	CA
3026851	Feb 2020	CA
1297140	May 2001	CN
1859943	Nov 2006	CN
101208699	Jun 2008	CN
4200595	Jul 1993	DE
19627619	Jan 1998	DE
19756872	Jul 1999	DE
19912459	Sep 2000	DE
10236669	Feb 2004	DE
202005012358	Oct 2005	DE
200401893	Dec 2004	DK
0026056	Apr 1981	EP
0062974	Oct 1982	EP
0098592	Jan 1984	EP
0275213	Jul 1988	EP
0341049	Nov 1989	EP
0496141	Jul 1992	EP
0496305	Jul 1992	EP
0549341	Jun 1993	EP
0580723	Feb 1994	EP
0612004	Aug 1994	EP
0721358	Jul 1996	EP
0867196	Sep 1998	EP
0939451	Sep 1999	EP
1045146	Oct 2000	EP
1136698	Sep 2001	EP
1376759	Jan 2004	EP
1177802	Sep 2004	EP
1491144	Dec 2004	EP
1495775	Jan 2005	EP
1527792	May 2005	EP
1571582	Sep 2005	EP
0801578	Jul 2006	EP
1754498	Feb 2007	EP
1818664	Aug 2007	EP
1824536	Aug 2007	EP
1951340	Aug 2008	EP
2139382	Jan 2010	EP
2397181	Dec 2011	EP
2468338	Jun 2012	EP
2666520	Nov 2013	EP
2695573	Feb 2014	EP
2703024	Mar 2014	EP
2764881	Aug 2014	EP
2830499	Feb 2015	EP
2897071	Jul 2015	EP
2943149	Nov 2015	EP
3177344	Jun 2017	EP
3193979	Jul 2017	EP
3314548	May 2018	EP
3607985	Feb 2020	EP
2096275	Feb 1972	FR
2585252	Jan 1987	FR
0747701	Apr 1956	GB
1125897	Sep 1968	GB
2218831	Nov 1989	GB
2443261	Apr 2008	GB
51-125993	Nov 1976	JP
02-131777	May 1990	JP
09-504974	May 1997	JP
11-010036	Jan 1999	JP
2000-513974	Oct 2000	JP
2002-085556	Mar 2002	JP
2002-507459	Mar 2002	JP
2002-523149	Jul 2002	JP
2003-531691	Oct 2003	JP
2004-283378	Oct 2004	JP
2005-326943	Nov 2005	JP
2007-525276	Sep 2007	JP
2008-513142	May 2008	JP
2010-502361	Jan 2010	JP
2010-524639	Jul 2010	JP
2012-527981	Nov 2012	JP
2017-516548	Jun 2017	JP
2017-525451	Sep 2017	JP
2018-153569	Oct 2018	JP
2019-525276	Sep 2019	JP
200740148	Oct 2007	TW
M452390	May 2013	TW
8606796	Nov 1986	WO
9015928	Dec 1990	WO
9509021	Apr 1995	WO
9721457	Jun 1997	WO
9800193	Jan 1998	WO
9804301	Feb 1998	WO
9811927	Mar 1998	WO
9855073	Dec 1998	WO
9857683	Dec 1998	WO
9907425	Feb 1999	WO
9910040	Mar 1999	WO
9910049	Mar 1999	WO
9921596	May 1999	WO
9939118	Aug 1999	WO
9948546	Sep 1999	WO
9956803	Nov 1999	WO
9962576	Dec 1999	WO
0030705	Jun 2000	WO
0032258	Jun 2000	WO
0048112	Aug 2000	WO
0154753	Aug 2001	WO
0172354	Oct 2001	WO
0172360	Oct 2001	WO
0178812	Oct 2001	WO
0191822	Dec 2001	WO
0191833	Dec 2001	WO
0215954	Feb 2002	WO
0226282	Apr 2002	WO
0240083	May 2002	WO
0243866	Jun 2002	WO
0257627	Jul 2002	WO
0268015	Sep 2002	WO
0276535	Oct 2002	WO
0281012	Oct 2002	WO
0282990	Oct 2002	WO
0284336	Oct 2002	WO
2002100469	Dec 2002	WO
0316882	Feb 2003	WO
0323728	Mar 2003	WO
0326728	Mar 2003	WO
0326726	Apr 2003	WO
0339362	May 2003	WO
0345233	Jun 2003	WO
0397133	Nov 2003	WO
2003103763	Dec 2003	WO
2004041330	May 2004	WO
2004043250	May 2004	WO
2004056412	Jul 2004	WO
2004092715	Oct 2004	WO
2004093648	Nov 2004	WO
2004110526	Dec 2004	WO
2005002652	Jan 2005	WO
2005011779	Feb 2005	WO
2005011799	Feb 2005	WO
2005039673	May 2005	WO
2005051170	Jun 2005	WO
2005072794	Aug 2005	WO
2005072795	Aug 2005	WO
2005082436	Sep 2005	WO
2005110601	Nov 2005	WO
2005113036	Dec 2005	WO
2006053007	May 2006	WO
2006061354	Jun 2006	WO
2006067217	Jun 2006	WO
2006075016	Jul 2006	WO
2006097453	Sep 2006	WO
2006105792	Oct 2006	WO
2006105793	Oct 2006	WO
2006105794	Oct 2006	WO
2007005219	Jan 2007	WO
2007056247	May 2007	WO
2007056504	May 2007	WO
2007056592	May 2007	WO
2007064835	Jun 2007	WO
2007066152	Jun 2007	WO
2007071255	Jun 2007	WO
2007078937	Jul 2007	WO
2007078992	Jul 2007	WO
2007141786	Dec 2007	WO
2008016621	Feb 2008	WO
2008024810	Feb 2008	WO
2008029403	Mar 2008	WO
2008073609	Jun 2008	WO
2008089184	Jul 2008	WO
WO-2008103175	Aug 2008	WO
2008-133702	Nov 2008	WO
2008134146	Nov 2008	WO
2009032402	Mar 2009	WO
2009035759	Mar 2009	WO
2009039203	Mar 2009	WO
2009045462	Apr 2009	WO
2009049252	Apr 2009	WO
2009066287	May 2009	WO
2009066288	May 2009	WO
2009098648	Aug 2009	WO
2009134380	Nov 2009	WO
2010022069	Feb 2010	WO
2010045460	Apr 2010	WO
2010053702	May 2010	WO
2010077279	Jul 2010	WO
2010097796	Sep 2010	WO
2010132077	Nov 2010	WO
2010138848	Dec 2010	WO
2010139793	Dec 2010	WO
2010147659	Dec 2010	WO
2011031458	Mar 2011	WO
2011075042	Jun 2011	WO
2011095483	Aug 2011	WO
2011133823	Oct 2011	WO
2012045667	Apr 2012	WO
2012073032	Jun 2012	WO
2012108959	Aug 2012	WO
2012134588	Oct 2012	WO
2012177353	Dec 2012	WO
2012178134	Dec 2012	WO
2013050535	Apr 2013	WO
2013078200	May 2013	WO
2013134486	Sep 2013	WO
2013149186	Oct 2013	WO
2013177565	Nov 2013	WO
2013182321	Dec 2013	WO
2014029416	Feb 2014	WO
2014035672	Mar 2014	WO
2014062399	Apr 2014	WO
2014074476	May 2014	WO
2014109898	Jul 2014	WO
2014110538	Jul 2014	WO
2014134459	Sep 2014	WO
2014149357	Sep 2014	WO
2014172467	Oct 2014	WO
2014179774	Nov 2014	WO
2014194183	Dec 2014	WO
2015056259	Apr 2015	WO
2015061493	Apr 2015	WO
2015073211	May 2015	WO
2015081337	Jun 2015	WO
2015117082	Aug 2015	WO
2015117854	Aug 2015	WO
2015167201	Nov 2015	WO
2015177082	Nov 2015	WO
2015187366	Dec 2015	WO
2015191459	Dec 2015	WO
2016004088	Jan 2016	WO
2016004210	Jan 2016	WO
2016022650	Feb 2016	WO
2016041873	Mar 2016	WO
2016089702	Jun 2016	WO
2016141082	Sep 2016	WO
2016161254	Oct 2016	WO
2017004278	Jan 2017	WO
2017091624	Jun 2017	WO
2017105600	Jun 2017	WO
2017184988	Oct 2017	WO
2017187177	Nov 2017	WO
2017205816	Nov 2017	WO
2018009614	Jan 2018	WO
2018067748	Apr 2018	WO
2018120104	Jul 2018	WO
2018136799	Jul 2018	WO
2018204568	Nov 2018	WO
2019077482	Apr 2019	WO
2019094440	May 2019	WO
2019213493	Nov 2019	WO
2019246381	Dec 2019	WO
2020081393	Apr 2020	WO
2021011738	Jan 2021	WO

Non-Patent Literature Citations (44)

Entry
US 5,954,699 A, 09/1999, Jost et al. (withdrawn)
“Minimed Inc. Introduces 407C Infusion Pump for General Medication Use” [online]. Business Wire, AllBusiness.com, Aug. 10, 1999 [retrieved on Feb. 28, 2011]. Retrieved from the Internet: <URL: http://www.allbusiness.com/company-activities-management/product-management/6734565-1.html>.
“Using the Deltec Cozmo Insulin Pump Correction Bolus Feature” believed to be publicly available before May 5, 2008, pp. 36-41.
“Which Insulin Pump is Right for Me?”, Albany Medical Center, Goodman Diabetes Service, Jan. 2006, 4 pages.
Accu-Chek Spirit, “Pump Therapy Made for You,” Roche, 2006, 6 pages.
Animas Corporation, IR1200 User Guide Manual, pp. 29-31, revised Sep. 2006.
Asante Pearl, Insulin Pump User Manual, 2012 (180 pages).
Asante Solutions Pearl User Manual, Asante Inc., 2012, 180 pages.
Brown et al., “CGM, Pumps, and SMBG.” American Diabetes Association—71st Scientific Sessions, San Diego, CA, Jun. 24-28, 2011, 38 pages.
Collins and Lee, “Microfluidic flow transducer based on the measurement of electrical admittance,” Lab Chip, 2003, 12 pages.
Copp et al., “Simultaneous Model Predictive Control and Moving Horizon Estimation for Blood Glucose Regulation in Type 1 Diabetes,” Optim. Control Appl. Meth. 2016, 15 pages.
Cox et al. “Prediction of Severe Hypoglycemia.” Diabetes Care, vol. 30, No. 6, Jun. 2007, 4 pages.
Dassau et al., “12-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin AIc and Hypoglycemia” Diabetes Care, Dec. 1, 2017, 40(12):1719-26.
Debiotech News Release, “Debiotech reveals its new miniaturized Disposable Insulin Nanopump. TM. for Diabetes therapy,” available at http://www.debiotech.com/news/nw_159.html Apr. 24, 2006, 3 pages.
Debiotech SA; Debiotech reveals its new miniaturized Disposable Insulin Nanopump} for Diabetes therapy (news release); retrieved from the internet: (http://web.archive.org/web/20060822033820/http://www.debiotech.com/news/nw_159.html); 3 pgs.; Apr. 24, 2006.
DOCNews; The latest in high-tech and convenient devices; American Diabetes Assoc.; 2(7); retrieved from the internet: (http://web.archive.org/web/20080526162751/http://docnews.diabetesjournals.org/cgi/content/full/2/7/13?); 3 pgs.; Jul. 1, 2005.
Duden Deutsches Universaiworterbuch, Dudenveriag, Mannheim, 1989, p. 822.
Dumont, “Feedback control for clinicians,” Journal of clinical monitoring and computing, Feb. 1, 2014, 28(1):5-11.
Fischer et al., “In Vivo Comparison of Different Algorithms for the Artificial Beta-Cell,” Artificial organs, May 1, 1985, 9(2):173-9.
Guarnieri et al. .; Flexible versus rigid catheters for chronic administration of exogenous agents into central nervous system tissues (abstract only); J Neurosc Meth; 144(2); pp. 147-152; Jun. 2005.
Honan, Matthew. “Apple unveils iPhone” Jan. 9, 2007. MacCentral. Accessed Dec. 29, 2011. 2 pages.
Hornby et al.; Catheter (definition); Oxford Advanced Learners Dictionary, 4th Ed.; Oxford University Press; Oxford, UK; p. 178; Apr. 1989.
Insulet Corporation; Innovative New System for Managing Diabetes Receives FDA Clearance; The OmniPod (Registered) Insulin Management System (press release); retrieved from the internet: (http://phx.corporate-ir.net/phoenix.zhtml? c=209336&p=irol-newsArticle_pf&ID=988708&highlight=); 2 pgs.; Feb. 1, 2005.
Insulet Corporation; OmniPod (Registered) Insulin Management System (quick-start guide); 2 pgs.; (Copyright) 2008.
International Search Report and Written Opinion in International Application No. PCT/US2014/67665, dated Apr. 21, 2015, 13 pages.
Keith Hynes et al., “DiAs User Interface: A Patient-Centric Interface for Mobile Artificial Pancreas Systems,” J Diabetes Sci Tech 7(6):1416-1426, Nov. 2013.
Kovatchev B. P. et al.: “Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas”, Diabetes Care, vol. 37, No. 7, Jun. 14, 2014 (Jun. 14, 2014), pp. 1789-1796.
Medtronic News Release, “Medtronic Receives FDA Approval for World's First Insulin Pump with Realtime Continuous Glucose Monitoring,” Apr. 13, 2006, 3 pages.
OmniPod Insulin Management System-Investor Relations—Press Release, Feb. 1, 2005, http://investors insulet.com/phoenix.zhtml?c=209336&p=irol-newsA-rdele&ID=988708&highlight=1 page.
OmniPod Quick Start Guide, 2007, 2 pages.
Percival et al., “Closed-Loop Control and Advisory Mode Evaluation of an Artificial Pancreatic Beta Cell: Use of Proportional-Integral-Derivative Equivalent Model-Based Controllers,” J Diabetes Sci Tech 2(4):636-644, Jul. 2008.
Salzsieder et al., “Estimation of individually adapted control parameters for an artificial beta cell,” Biomed. Biochim. Acta, Jan. 1, 1984, 43(5):585-596.
Shiavon et al., “Quantitative Estimation of Insulin Sensitivity in Type 1 Diabetic Subjects Wearing a Sensor-Augmented Insulin Pump,” Diabetes care, May 1, 2014, 37(5):1216-23.
The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Application for Low Glucose Suspend (LGS) Device System. Rockville, MD, Food and Drug Administration, 2011, 59 pages.
The Medtronic Diabetes Connection, 2006, 6 pages.
U.S. Appl. No. 60/753,684, filed Dec. 23, 2005.
U.S. Appl. No. 60/753,984, filed Dec. 23, 2005.
U.S. Appl. No. 60/734,382, filed Nov. 8, 2005, Mernoe, et al.
U.S. Appl. No. 11/362,616.
Vozeh et al., “Feedback Control Methods for Drug Dosage Optimisation, Concepts, Classifications and Clinical Application,” Clinical pharmacokinetics, Nov. 1, 1985, 10(6):457-76.
Walsh et al., “Guidelines for Insulin Dosing in Continuous Subcutaneious Insulin Infusion Using New Formulas from a Retrospective Study of Individuals with Optimal Glucose Levels”, J. Diabetes Science and Technology, vol. 4 Issue 5, Sep. 2010 (8 pages).
Walsh et al.,“Guidelines for Optimal Bolus Calculator Settings in Adults”, J. Diabetes Science and Technology; vol. 5 Issue 1; Jan. 2011 (7 pages).
Xilas Temp Touch, “The latest in high-tech and convenient devices,” DOCNews, vol. 2, No. 7, Jul. 1, 2005, http;//docnews.diabetesjournals.ord/cgi/content/full/2/7/13, 3 pages.
Australian Examination Report for Application No. 2021204821 dated Jul. 6, 2022, 4 pages.

Related Publications (1)

	Number	Date	Country
	20200368426 A1	Nov 2020	US

Divisions (1)

	Number	Date	Country
Parent	12195034	Aug 2008	US
Child	13071061		US

Continuations (4)

	Number	Date	Country
Parent	15948356	Apr 2018	US
Child	16947627		US
Parent	14797400	Jul 2015	US
Child	15948356		US
Parent	13524200	Jun 2012	US
Child	14797400		US
Parent	13071061	Mar 2011	US
Child	13524200		US

Infusion pump systems and methods

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract